Compound
berberine
An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
Studied for
25 endpoints · 56 findings · 30 papers · 10 null
- Fasting blood glucoselowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- HOMA-IRlowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- Body masslowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- Body mass indexlowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- Aspartate aminotransferaseno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Structure
Loading the model…
- Class
- Organic compound, cation
- Formula
- C20H18NO4
- Mass
- 336.367 g/mol
- Charge
- +1
- InChIKey
- YBHILYKTIRIUTE-UHFFFAOYSA-N
- SMILES
- COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2
- Look it up
- ChEBIPubChemBy InChIKey
Identity from ChEBI, geometry from PubChem. Not evidence.
What the evidence says
How to read these marks56 findings · 25 endpoints · 30 papers · 10 null · by evidence strength
- Evidence strength
- Strong
- Moderate
- Limited
- Very limited
- Insufficient
| Endpoint | Lowered38 findings, 15 endpoints | No detected effect10 findings, 8 endpoints | Raised2 findings, 2 endpoints | Other6 findings, 5 endpoints |
|---|---|---|---|---|
| Fasting blood glucose | ||||
| HOMA-IR | ||||
| Body mass | ||||
| Body mass index | ||||
| Aspartate aminotransferase | ||||
| Glycated haemoglobin (HbA1c) | ||||
| Total cholesterol (TC) | ||||
| Triglycerides | ||||
| LDL cholesterol | ||||
| Inhibits CYP2C9 | ||||
| Inhibits CYP3A4 | ||||
| Systolic blood pressure (setting unspecified) | ||||
| Alanine aminotransferase | ||||
| C-reactive protein concentration | ||||
| Interleukin-6 concentration | ||||
| Colorectal adenoma recurrence after polypectomy | ||||
| Inhibits NLRP3 | ||||
| Accumulates in liver | ||||
| Clinical pregnancy rate | ||||
| HDL cholesterol | ||||
| Inhibits EPHB2 | ||||
| Total testosterone | ||||
| Measured, and no finding detected an effect | ||||
| Adverse reaction incidence (unstandardised) | ||||
| Diastolic blood pressure (setting unspecified) | ||||
| Waist-to-hip ratio | ||||
What moved
46 findings
Decreases glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“BBR supplementation significantly decreased HbA1c compared to placebo (WMD = −0.45%; 95%CI, −0.68 to −0.23; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -0.45 mean difference, 95% CI -0.68 to -0.23
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Decreases total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“After 12 weeks of intervention, men taking berberine had a larger reduction in total cholesterol and HDL-c than those taking placebo (Table 2).”
Quoted verbatim from Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 500 mg twice daily
- Population
- Chinese men aged 20-65 years with hyperlipidemia; primary endpoint
Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial.2021PMID:34444711Permalink
Decreases triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“BBR significantly reduced TG compared to placebo (WMD = −23.70 mg/dl; 95% CI, −30.16 to −17.25; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -23.7 mean difference, 95% CI -30.16 to -17.25
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Decreases HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“Improved insulin resistance was assessed by lowering FINS (MD = -2.05, 95% CI (-2.62, -1.48)), HOMA-IR (MD = -0.71, 95% CI (-1.03, -0.39)), and BMI (MD = -1.07, 95% CI (-1.76, -0.37)).”
Quoted verbatim from The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with type 2 diabetes mellitus
The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2021PMID:34956436Permalink
Decreases triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“BBR exhibited greater decreases in body weight, BMI, waist, HFC, serum cholesterol and triglycerides compared with LSI alone (Additional file 1: Table S1), which demonstrates a clearly significant benefit of BBR on metabolism.”
Quoted verbatim from Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.. - Study
- RCT
- Duration
- 4 months
- Dose
- berberine 0.5 g three times daily, 30 min before meals
- Population
- Adults with nonalcoholic fatty liver disease and impaired glucose regulation or type 2 diabetes; lifestyle intervention (diet and exercise) given to both arms, berberine added in one; 80-patient lipidomics subsample (41 berberine, 39 lifestyle alone)
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.2016PMID:27629750Permalink
Decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“BBR supplementation significantly decreased weight compared to placebo (WMD = −0.84; 95%CI, −1.34 to −0.34; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -0.84 mean difference, 95% CI -1.34 to -0.34
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Show the remaining 40
Inhibits CYP2C9
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In addition, losartan/E-3174 ratio doubled (P<0.01) after BBR administration, indicating a decrease in CYP2C9 activity.”
Quoted verbatim from Repeated administration of berberine inhibits cytochromes P450 in humans.. - Study
- crossover
- Duration
- 14 days
- Dose
- berberine 300 mg three times daily orally for 14 days versus placebo; losartan 30 mg probe
- Population
- Healthy Chinese male volunteers, randomised two-phase crossover with 4-week washout; CYP2C9 activity read from the 0 to 8 h losartan to E-3174 ratio (in vivo probe)
Repeated administration of berberine inhibits cytochromes P450 in humans.2012PMID:21870106Permalink
Decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“BBR supplementation significantly decreased BMI compared to placebo (WMD = −0.25 kg/m2; 95%CI, −0.46 to −0.04; P = 0.020).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -0.25 mean difference, 95% CI -0.46 to -0.04
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Decreases HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×4“BBR supplementation significantly decreased HOMA-IR compared to placebo (WMD = −1.04; 95%CI, −1.55 to −0.52; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -1.04 mean difference, 95% CI -1.55 to -0.52
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Decreases systolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“BBR supplementation significantly decreased SBP compared to placebo (WMD = −5.46 mmHg; 95%CI, −8.17 to −2.76; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS, hypertension and other populations)
Effect -5.46 mean difference, 95% CI -8.17 to -2.76
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Decreases fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“BBR supplementation significantly decreased FBG compared to placebo (WMD = −7.74 mg/dl; 95%CI, −10.79 to −4.70; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -7.74 mean difference, 95% CI -10.79 to -4.7
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Decreases LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“BBR significantly reduced LDL compared to placebo (WMD = −9.63 mg/dl; 95%CI, −13.87 to −5.39; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -9.63 mean difference, 95% CI -13.87 to -5.39
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Decreases total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“BBR significantly reduced TC compared to placebo (WMD = −20.64 mg/dl; 95%CI, −23.65 to −17.63; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -20.64 mean difference, 95% CI -23.65 to -17.63
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Inhibits CYP3A4
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“CYP3A4 activity was also inhibited, as the Cmax, AUC0–∞, and AUC0–12 of mid-azolam were increased 38% (P<0.05), 40% (P<0.01), and 37% (P<0.05) after BBR treatment.”
Quoted verbatim from Repeated administration of berberine inhibits cytochromes P450 in humans.. - Study
- crossover
- Duration
- 14 days
- Dose
- berberine 300 mg three times daily orally for 14 days versus placebo; midazolam 2 mg probe
- Population
- Healthy Chinese male volunteers, randomised two-phase crossover with 4-week washout; CYP3A4 activity read from midazolam pharmacokinetics (in vivo probe)
Repeated administration of berberine inhibits cytochromes P450 in humans.2012PMID:21870106Permalink
Decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“BBR exhibited greater decreases in body weight, BMI, waist, HFC, serum cholesterol and triglycerides compared with LSI alone (Additional file 1: Table S1), which demonstrates a clearly significant benefit of BBR on metabolism.”
Quoted verbatim from Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.. - Study
- RCT
- Duration
- 4 months
- Dose
- berberine 0.5 g three times daily, 30 min before meals
- Population
- Adults with nonalcoholic fatty liver disease and impaired glucose regulation or type 2 diabetes; lifestyle intervention (diet and exercise) given to both arms, berberine added in one; 80-patient lipidomics subsample (41 berberine, 39 lifestyle alone)
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.2016PMID:27629750Permalink
Decreases body mass index
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“BBR exhibited greater decreases in body weight, BMI, waist, HFC, serum cholesterol and triglycerides compared with LSI alone (Additional file 1: Table S1), which demonstrates a clearly significant benefit of BBR on metabolism.”
Quoted verbatim from Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.. - Study
- RCT
- Duration
- 4 months
- Dose
- berberine 0.5 g three times daily, 30 min before meals
- Population
- Adults with nonalcoholic fatty liver disease and impaired glucose regulation or type 2 diabetes; lifestyle intervention (diet and exercise) given to both arms, berberine added in one; 80-patient lipidomics subsample (41 berberine, 39 lifestyle alone)
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.2016PMID:27629750Permalink
Decreases glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Thus, BBR and BBR with probiotics were both superior to the Plac in lowering HbA1c, but Prob was not.”
Quoted verbatim from Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).. - Study
- RCT
- Duration
- 3 months
- Dose
- 0.6 g twice daily
- Population
- newly diagnosed type 2 diabetes adults; berberine-alone arm vs placebo, primary outcome
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).2020PMID:33024120Industry fundedPermalink
Decreases colorectal adenoma recurrence after polypectomy
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Sensitivity analyses also demonstrated the same trend: patients in the berberine group had lower risk of colorectal adenoma recurrence (adjusted HR, 0.62; 95% CI: 0.49–0.79; p < 0.001) (Table S2).”
Quoted verbatim from Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial.. - Study
- cohort
- Population
- Patients with resected colorectal adenoma from the CBAR trial, extended 6-year post-treatment follow-up (CBAR-FE study); sensitivity-analysis estimate
Effect 0.62 hazard ratio, 95% CI 0.49 to 0.79
Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial.2025PMID:40795846Permalink
Decreases body mass index
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Berberine use significantly reduces body weight, BMI, and WC but does not significantly reduce WHR.”
Quoted verbatim from The effect of berberine on obesity indices: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- adults in randomized controlled trials of berberine for obesity indices
The effect of berberine on obesity indices: a systematic review and meta-analysis.2026PMID:41310257Permalink
Decreases glycated haemoglobin (HbA1c)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Berberine lowered fasting glucose (-0.52 mmol/L, 95% CI -0.72 to -0.33; 18 studies, n = 1522), HbA1c (-4.48 mmol/mol, 95% CI -6.53 to -2.44, 7 studies, n = 756), fasting insulin (-2.36 mU/L, 95% CI -3.64 to -1.08, 11 studies, n = 966), HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065), and 2-h postprandial glucose (-1.81 mmol/L, 95% CI -2.37 to -1.24, 4 studies, n = 501).”
Quoted verbatim from Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 756
- Population
- Adults in 20 randomized trials of berberine versus placebo, pooled across sexes and diabetes status
Effect -4.48 mean difference, 95% CI -6.53 to -2.44
Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.2023PMID:37598753Permalink
Decreases HOMA-IR
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“Berberine lowered fasting glucose (-0.52 mmol/L, 95% CI -0.72 to -0.33; 18 studies, n = 1522), HbA1c (-4.48 mmol/mol, 95% CI -6.53 to -2.44, 7 studies, n = 756), fasting insulin (-2.36 mU/L, 95% CI -3.64 to -1.08, 11 studies, n = 966), HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065), and 2-h postprandial glucose (-1.81 mmol/L, 95% CI -2.37 to -1.24, 4 studies, n = 501).”
Quoted verbatim from Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 1,065
- Population
- Adults in 20 randomized trials of berberine versus placebo, pooled across sexes and diabetes status
Effect -0.85 mean difference, 95% CI -1.16 to -0.53
Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.2023PMID:37598753Permalink
Decreases LDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”
Quoted verbatim from The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- berberine 900 mg/day
- Population
- patients with schizophrenia, berberine given as adjunctive treatment
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.2021PMID:33812218Permalink
Decreases total cholesterol (TC)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”
Quoted verbatim from The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- berberine 900 mg/day
- Population
- patients with schizophrenia, berberine given as adjunctive treatment
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.2021PMID:33812218Permalink
Decreases C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Pooled analysis showed that serum levels of CRP were decreased after BER supplementation (MD:-0.64 mg/L, 95% CI(-0.67 to -0.61) P < 0.001)) without any significant heterogeneity (I2 = 0.0% and P = 0.984).”
Quoted verbatim from Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults in randomized controlled trials of berberine supplementation
Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.2019PMID:31519292Permalink
Decreases C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“From the baseline to the 8th week, the plasma CRP concentration decreased in the berberine group, while increased in the placebo group (F = 5.373; p = 0.024).”
Quoted verbatim from Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- berberine 900 mg/day, oral, 8 weeks
- Population
- patients with schizophrenia, berberine given adjunctive to a single atypical antipsychotic drug
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.2022PMID:35037116Permalink
Increases clinical pregnancy rate
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Berberine in combination with Western medicine significantly improved endometrial thickness (weight mean difference [WMD] 1.62 mm; 95 % confidence interval [CI] 1.39-1.85), ovulation rate (risk ratio [RR] 1.41; 95 % CI 1.26-1.60), and clinical pregnancy rate (RR 1.96; 95 % CI 1.59-2.41) compared to Western medicine alone.”
Quoted verbatim from Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Women with polycystic ovary syndrome and reduced fertility potential; berberine added to Western medicine versus Western medicine alone (10 RCTs pooled)
Effect 1.96 risk ratio, 95% CI 1.59 to 2.41
Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials.2024PMID:39236662Permalink
Decreases fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“FPG, FPI, HOMA-IR, HbA1, TG, BMI, and WC were significantly lower in patients who received berberine compared to placebo after 12 weeks of treatment ([Formula: see text]< 0.05).”
Quoted verbatim from Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.. - Study
- RCT
- Duration
- 3 months
- Population
- patients with schizophrenia, bipolar disorder, or schizoaffective psychosis with olanzapine-induced mild metabolic disorders, continuing olanzapine treatment (background, both arms)
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.2021PMID:34961418Permalink
Inhibits NLRP3
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Compared with the findings in 5-FU group, the expression level of NLRP3 in the spleen significantly decreased and that of IL-10 significantly increased in the Ber-CD and Con-Ber groups (p < 0.05).”
Quoted verbatim from Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents.. - Study
- animal · not in humans
- Duration
- 3 days
- Dose
- native berberine (Con-Ber) 5 mg/kg/day, intraperitoneal, days 3-5
- Population
- C57BL/6 mice with 5-fluorouracil-induced intestinal mucositis, spleen
Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents.2023PMID:36903391Permalink
Decreases interleukin-6 concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Oral berberine significantly decreased lipopolysaccharide, CRP (C-reactive protein), and IL (interleukin)-6 levels.”
Quoted verbatim from Preventive Effect of Berberine on Postoperative Atrial Fibrillation.. - Study
- RCT
- Population
- patients undergoing isolated coronary artery bypass grafting
Preventive Effect of Berberine on Postoperative Atrial Fibrillation.2022PMID:36178742Permalink
Decreases HOMA-IR
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“FPG, FPI, HOMA-IR, HbA1, TG, BMI, and WC were significantly lower in patients who received berberine compared to placebo after 12 weeks of treatment ([Formula: see text]< 0.05).”
Quoted verbatim from Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.. - Study
- RCT
- Duration
- 3 months
- Population
- patients with schizophrenia, bipolar disorder, or schizoaffective psychosis with olanzapine-induced mild metabolic disorders, continuing olanzapine treatment (background, both arms)
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.2021PMID:34961418Permalink
Decreases total testosterone
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Moreover, berberine as adjuvant therapy also significantly reduced the blood levels of luteinizing hormone (WMD -2.07 U/L; 95 % CI -2.62 to -1.51) and total testosterone (standard mean difference -0.70; 95 % CI -1.02 to -0.39) but not the level of follicle-stimulating hormone level (WMD -0.23 IU/L; 95 % CI -0.52 to 0.06).”
Quoted verbatim from Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Women with polycystic ovary syndrome and reduced fertility potential; berberine added to Western medicine versus Western medicine alone (10 RCTs pooled)
Effect -0.7 standardised mean difference, 95% CI -1.02 to -0.39
Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials.2024PMID:39236662Permalink
Decreases alanine aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“After a 12-week intervention, the BBR group demonstrated a statistically significant decrease in alanine transaminase (ALT) p=0.0105, and de Ritis ratio p=0.0011 compared to the control group.”
Quoted verbatim from Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- berberine 1500 mg/day, oral, 12 weeks
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD)
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.2024PMID:39042390Permalink
Decreases body mass index
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“FPG, FPI, HOMA-IR, HbA1, TG, BMI, and WC were significantly lower in patients who received berberine compared to placebo after 12 weeks of treatment ([Formula: see text]< 0.05).”
Quoted verbatim from Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.. - Study
- RCT
- Duration
- 3 months
- Population
- patients with schizophrenia, bipolar disorder, or schizoaffective psychosis with olanzapine-induced mild metabolic disorders, continuing olanzapine treatment (background, both arms)
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.2021PMID:34961418Permalink
Increases HDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Berberine also increased the level of high-density lipoprotein cholesterol (HDL-C) when used alone (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001).”
Quoted verbatim from Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- patients with dyslipidaemias
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.2018PMID:30466986Permalink
Accumulates in liver
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“As shown in Fig 4, BBR and its metabolites were distributed in the liver.”
Quoted verbatim from Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.. - Study
- animal · not in humans
- Dose
- single oral dose 200 mg/kg
- Population
- High-fat-diet-induced NAFLD male Sprague-Dawley rats, liver sampled 0 to 48 h after a single oral dose
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.2015PMID:26252777Permalink
Decreases HOMA-IR
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“As shown in Figure 1, BF treatment significantly increased plasma FINS, T-SOD, GSH-PX, and GLP-1 and reduced FBG, HOMA-IR, and plasma TG, TC, and GSP (all P < 0.05) in diabetic rats.”
Quoted verbatim from Hypoglycemic Mechanism of the Berberine Organic Acid Salt under the Synergistic Effect of Intestinal Flora and Oxidative Stress.. - Study
- animal · not in humans
- Dose
- 500 mg/kg per day berberine fumarate by intragastric administration for 4 weeks
- Population
- Streptozotocin plus high-fat high-sucrose diet type 2 diabetic Sprague-Dawley rats given berberine fumarate versus distilled-water-treated diabetic rats
Hypoglycemic Mechanism of the Berberine Organic Acid Salt under the Synergistic Effect of Intestinal Flora and Oxidative Stress.2018PMID:30662584Permalink
Decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Furthermore, the FBG, RBG and TG in BBR- and HGSD-treated mice were significantly lower than those in db/db mice, and the OGTT and ITT were significantly improved compared with those in the db/db group.”
Quoted verbatim from Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2β/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 β-cells.. - Study
- animal · not in humans
- Dose
- berberine 160 mg/kg daily for 4 weeks
- Population
- Male db/db mice treated with berberine alone versus saline-treated db/db mice; the sentence pools berberine-treated and Huang-Gui Solid Dispersion-treated mice
Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2β/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 β-cells.2019PMID:31337982Permalink
Decreases C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Oral berberine significantly decreased lipopolysaccharide, CRP (C-reactive protein), and IL (interleukin)-6 levels.”
Quoted verbatim from Preventive Effect of Berberine on Postoperative Atrial Fibrillation.. - Study
- RCT
- Population
- patients undergoing isolated coronary artery bypass grafting
Preventive Effect of Berberine on Postoperative Atrial Fibrillation.2022PMID:36178742Permalink
Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“After the 16-week BBR intervention, the NAFLD + BBR group (736 ± 20.80) exhibited a significant reduction in body weight compared with the NAFLD group (828.67 ± 86.78) (P < 0.05, Fig. 3a).”
Quoted verbatim from Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.. - Study
- animal · not in humans
- Dose
- 150 mg/kg body weight per day by gavage for 16 weeks
- Population
- Male Sprague-Dawley rats with high-fat-diet-induced non-alcoholic fatty liver disease; berberine versus normal-saline gavage, body weight at end of 16-week intervention
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.2017PMID:28241817Permalink
Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“These results showed at 20 weeks the body weight significantly increased in HF group compared with NCD group (P<0.01), whereas BBR significantly suppressed body weight of mice with a high-fat diet in a dose-dependent manner (P<0.01).”
Quoted verbatim from Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.. - Study
- animal · not in humans
- Dose
- 25 or 100 mg/kg daily by gavage, from 14 to 20 weeks of age
- Population
- Male C57BL/6J mice fed a high-fat diet; berberine 25 and 100 mg/kg versus saline gavage, body weight at 20 weeks of age
Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.2021PMID:34421358Permalink
Inhibits EPHB2
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The Western blot results further indicated that BBR not only inhibited PA/LPS-induced CHOP and ATF-4 activation but also significantly suppressed PA/LPS-induced ERK activation in primary mouse hepatocytes.”
Quoted verbatim from Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes.. - Study
- in vitro · not in humans
- Dose
- 5 uM for 1 h pretreatment
- Population
- Primary mouse hepatocytes from C57BL/6 mice pretreated with berberine 5 uM for 1 h, then palmitic acid and LPS for 6 h
Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes.2020PMID:32357187Permalink
Decreases fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Berberine lowered fasting glucose (-0.52 mmol/L, 95% CI -0.72 to -0.33; 18 studies, n = 1522), HbA1c (-4.48 mmol/mol, 95% CI -6.53 to -2.44, 7 studies, n = 756), fasting insulin (-2.36 mU/L, 95% CI -3.64 to -1.08, 11 studies, n = 966), HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065), and 2-h postprandial glucose (-1.81 mmol/L, 95% CI -2.37 to -1.24, 4 studies, n = 501).”
Quoted verbatim from Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Participants
- 1,522
- Population
- Adults in 20 randomized trials of berberine versus placebo, pooled across sexes and diabetes status
Effect -0.52 mean difference, 95% CI -0.72 to -0.33
Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.2023PMID:37598753Permalink
Decreases aspartate aminotransferase
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“However, oral administration of BBR not only reversed hepatocyte necrosis, but also decreased the elevated levels of TBA, ALP, TBIL, DBIL, ALT, and AST ( Supplementary Fig. 1A, 1B).”
Quoted verbatim from Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.. - Study
- animal · not in humans
- Duration
- 7 days
- Population
- C57BL/6J mice with bile duct ligation-induced cholestatic liver injury; serum AST by automated biochemical analyser
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.2026PMID:41087029Permalink
Decreases fasting blood glucose
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×3“In comparison to the Con group, FBG levels in the BBR group were reduced during the initial period (p <.05) and were continually reduced in the Sta + BBR group (p <.05; Figure 1a).”
Quoted verbatim from Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.. - Study
- animal · not in humans
- Dose
- 100 mg/kg once daily by gavage for 55 days
- Population
- Type 2 diabetic db/db mice given berberine alone versus water-treated diabetic controls; the berberine-alone reduction is reported for the initial treatment period only
Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.2020PMID:31833107Permalink
Decreases alanine aminotransferase
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×1“However, oral administration of BBR not only reversed hepatocyte necrosis, but also decreased the elevated levels of TBA, ALP, TBIL, DBIL, ALT, and AST ( Supplementary Fig. 1A, 1B).”
Quoted verbatim from Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.. - Study
- animal · not in humans
- Duration
- 7 days
- Population
- C57BL/6J mice with bile duct ligation-induced cholestatic liver injury; serum ALT by automated biochemical analyser
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.2026PMID:41087029Permalink
Inhibits NLRP3
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×1“The qRT-PCR results showed that BBR dose-dependently inhibited the mRNA expression of NLRP3 and its linked molecules, including IL-1β, caspase-1, ASC, and GSDMAD.”
Quoted verbatim from Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration.. - Study
- animal · not in humans
- Duration
- 4 weeks
- Dose
- 60-240 mg/kg/day, daily oral gavage, days 1-28
- Population
- C57BL/6J mice with sciatic nerve crush injury (peripheral nerve injury), injury-site tissue
Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration.2024PMID:38570276Permalink
What did not
10 findings
No detected effect on adverse reaction incidence (unstandardised)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Nonetheless, the impact of BBR on reducing adverse reactions was not statistically significant (RR = 0.75, 95% CI [0.42, 1.33], P > 0.05).”
Quoted verbatim from Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- patients with ulcerative colitis; berberine plus 5-aminosalicylic acid versus 5-aminosalicylic acid
Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis.2024PMID:39241013Permalink
No detected effect on aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“The effect of BBR supplementation on AST was non-significant (WMD = −2.94; 95%CI, −8.68 to 2.81; P = 0.316).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (nine effect sizes pooled)
Effect -2.94 mean difference, 95% CI -8.68 to 2.81
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
No detected effect on diastolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The effect of BBR supplementation on DBP was non-significant (WMD = −2.74 mmHg; 95%CI, −5.63 to 0.15; P = 0.063).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS, hypertension and other populations)
Effect -2.74 mean difference, 95% CI -5.63 to 0.15
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
No detected effect on alanine aminotransferase
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1“The effect of BBR supplementation on ALT was non-significant (WMD = −4.22; 95%CI, −8.75 to 0.31; P = 0.068) (Table 3).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (12 effect sizes pooled)
Effect -4.22 mean difference, 95% CI -8.75 to 0.31
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
No detected effect on C-reactive protein concentration
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“The effect of BBR supplementation on CRP was non-significant (WMD = 0.05; 95%CI, −0.59 to 0.68; P = 0.887).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect 0.05 mean difference, 95% CI -0.59 to 0.68
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
No detected effect on interleukin-6 concentration
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“The effect of BBR supplementation on IL-6 was non-significant (WMD = −0.53; 95%CI, −1.11 to 0.05; P = 0.073).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.. - Study
- meta-analysis
- Population
- Adults in randomised controlled trials of berberine (four trials pooled)
Effect -0.53 mean difference, 95% CI -1.11 to 0.05
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
Show the remaining 4
No detected effect on alanine aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“However, berberine intake did not affect liver enzymes, including alanine aminotransferase (ALT) (WMD = -1.66 I/U, 95% CI -3.98, 0.65, P = 0.160) and aspartate aminotransferase (AST) (WMD = -0.87 I/U, 95% CI -2.56, 0.82, P = 0.311).”
Quoted verbatim from The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with obesity or metabolic disorders; meta-analysis of 12 RCTs
The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.2020PMID:32690176Permalink
No detected effect on aspartate aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“However, berberine intake did not affect liver enzymes, including alanine aminotransferase (ALT) (WMD = -1.66 I/U, 95% CI -3.98, 0.65, P = 0.160) and aspartate aminotransferase (AST) (WMD = -0.87 I/U, 95% CI -2.56, 0.82, P = 0.311).”
Quoted verbatim from The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults with obesity or metabolic disorders; meta-analysis of 12 RCTs
The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.2020PMID:32690176Permalink
No detected effect on fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Notably, compared with the placebo, BBR did not change fasting blood glucose (FBG), fasting insulin or fasting proinsulin C-peptide levels (Supplementary Table 2).”
Quoted verbatim from Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.. - Study
- crossover
- Participants
- 15
- Dose
- single oral dose of 1 g berberine tablets
- Population
- 15 healthy men with normal glucose tolerance; secondary observation in a single-dose hyperglycaemic clamp trial, fasting glucose measured after an overnight fast before and after dosing
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.2021PMID:34556670Permalink
No detected effect on waist-to-hip ratio
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“However, berberine did not significantly reduce WHR compared to control groups (MD of -0.01, 95% CI: -0.03 to 0.01).”
Quoted verbatim from The effect of berberine on obesity indices: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- adults in randomized controlled trials of berberine for obesity indices
The effect of berberine on obesity indices: a systematic review and meta-analysis.2026PMID:41310257Permalink
What it touches on the way
Mechanistic reach
2 entities
2 entities reached.
0 reported hops2 assembled from the scaffold
What the reference databases state
Regulatory determinations
LiverTox likelihood score ELiverTox
LiverTox Likelihood Score E — despite extensive use, no evidence that the agent has caused liver injury. Chapter: "Berberine". Source: LiverTox Master List (NBK571102).
The document·Public Domain (NLM/NIH)·Transcribed, not assessed
Reactions
3 reactions
CHEBI:16592+2dioxygen+hydronberberine+2hydrogen peroxide
Reaction pageDirection not assertedBalanced
Rhea RHEA:13489CC BY 4.0Reference data
CHEBI:18146+2NADP(3-)berberine+2NADPH(4-)+hydron
Reaction pageDirection not assertedBalanced
Rhea RHEA:21268CC BY 4.0Reference data
2CHEBI:15920+dioxygen2berberine+2water
Reaction pageDirection not assertedBalanced
Rhea RHEA:23564CC BY 4.0Reference data
On the label
Labelled products
349 products
Source: NIH DSLD · Ingredient: berberine · 349 products · Declared amount per serving: 1–1,500 mg (338 products)
348 labels state an amount1 does not
- 1MDGlucoseMDBerberidaceae bark extract500 mgper 1 Capsule(s)DSLD:246741
- 5% CoreGDABerberis aristata500 mgper 3 Capsule(s)DSLD:333960
- Absolute NutritionBerberineBerberis aristata1,200 mgper 2 Capsule(s)DSLD:328932
- Absorb HealthBerberine 450 mgBerberis aristata · Berberine HCl (Form: from Berberis aristata CorrectedName: Berberis aristata PlantPart: Root Genus: Berberis Species: aristata)900 mgper 2 Capsule(s)DSLD:215743
- Advance Physician FormulasBerberine 500 mgIndian Barberry Root Extract500 mgper 1 Capsule(s)DSLD:337920
- Advanced Nutrition by ZahlerDiabetter1 Gram(s)per 4 Capsule(s)DSLD:316631
- AgeImmuneBrilliant Berberine 1000 mg1,000 mgper 2 Capsule(s)DSLD:268712
- AgeImmuneBrilliant Berberine 1000 mgBerberis aristata1,000 mgper 2 Capsule(s)DSLD:317907
- Akasha NaturalsCandi-Free400 mgper 2 Tablet(s)DSLD:313104
- Alive By ScienceLIPO BerberineLIPO150 mgper 1 Vegetarian Capsule(s)DSLD:264760
- Allergy Research GroupGlucose Tolerance II with Glucevia500 mgper 2 Capsule(s)DSLD:233517
- Allergy Research GroupTricycline400 mgper 1 Capsule(s)DSLD:258404
Show the remaining 337
- Alpha LionGains Candy GlucovantageDihydroberberine100 mgper 1 Capsule(s)DSLD:308299
- Alpha Lion Gains Candy GlucoVantageDihydroberberine100 mgper 1 Capsule(s)DSLD:268665
- Ambrosia CollectiveAlkemiDihydroberberine100 mgper 2 Capsule(s)DSLD:334097
- Ambrosia CollectiveEmberDihydroberberine50 mgper 1 Tablet(s)DSLD:271696
- AN Amazing Nutrition Amazing FormulasBerberine 1,000 mg1,000 mgper 1 Capsule(s)DSLD:251459
- AN Amazing Nutrition Amazing FormulasBerberine 1,000 mg1,000 mgper 2 Capsule(s)DSLD:255713
- AN Amazing Nutrition Amazing FormulasBerberine 1,000 mg1,000 mgper 2 Capsule(s)DSLD:255743
- AN Amazing Nutrition Amazing FormulasBerberine 1,000 mg1,000 mgper 2 Capsule(s)DSLD:255748
- AN Amazing Nutrition Amazing FormulasBerberine 1,200 mg1,200 mgper 2 Veggie Capsule(s)DSLD:255745
- AN Amazing Nutrition Amazing FormulasBerberine 1,200 mg1,200 mgper 2 Veggie Capsule(s)DSLD:255746
- AN Amazing Nutrition Amazing FormulasBerberine Complex1,000 mgper 2 Veggie Capsule(s)DSLD:251460
- AN Amazing Nutrition Amazing FormulasBerberine Complex1,000 mgper 2 Veggie Capsule(s)DSLD:255747
- AN Amazing Nutrition Amazing FormulasBerberine, Turmeric & BioPerineBerberis aristata400 mgper 3 Veggie Capsule(s)DSLD:251345
- AN Amazing Nutrition Amazing FormulasQuercetin Berberine 500 mg250 mgper 1 Veggie Capsule(s)DSLD:251568
- AN Amazing Nutrition Amazing FormulasQuercetin Berberine 500 mg250 mgper 1 Veggie Capsule(s)DSLD:256143
- Anabolic WarfarePeoject GDABerberis aristata200 mgper 3 Capsule(s)DSLD:307033
- Ancient BlissBerberine +Plus1,200 mgper 2 Capsule(s)DSLD:331353
- Arms Race NutritionStabilize1,200 mgper 5 Capsule(s)DSLD:241241
- Arms Race NutritionStabilize Hers1,200 mgper 2 Capsule(s)DSLD:308166
- Arms Race NutritionStabilize His1,200 mgper 3 Capsule(s)DSLD:308167
- AvalonX Powered by MDLogicBerberine 500Berberine HCl Dihydrate1,000 mgper 1 Capsule(s)DSLD:320614
- AXIS NutritionAdvanced Digestive SupportBerberine Hydrochloride150 mgper 2 Capsule(s)DSLD:298747
- Babe by Bucked UpBabe Bikini100 mgper 3 Capsule(s)DSLD:325580
- Balance OneCandAssist100 mgper 3 Capsule(s)DSLD:299273
- Balance OneCandida Cleanse100 mgper 3 Capsule(s)DSLD:233375
- Barlean's PlatinumIntestinal Repair Mixed Berry Flavor1 mgper 6 Gram(s)DSLD:314168
- Best NaturalsBerberine 500 mg500 mgper 1 Capsule(s)DSLD:269295
- Best NaturalsBerberine Plus 1000 mg1,000 mgper 2 Capsule(s)DSLD:269296
- Best NaturalsBerberine Plus 1000 mg1,000 mgper 2 Capsule(s)DSLD:270351
- Beyond HealthBerberine 500 mgBerberis aristata · 97%, Indian Barberry500 mgper 1 Capsule(s)DSLD:306877
- Bio NutritionAdvanced Berberine 12001,200 mgper 2 Vegetarian CapsulesDSLD:81221
- BiOptimizersBlood Sugar BreakthroughDihydroberberine100 mgper 2 Capsule(s)DSLD:320981
- Botanic ChoiceBerberine 500 mgBerberis aristata · Berberine HCl Dihydrate (Form: from Berberis aristata PlantPart: root Genus: Berberis Species: aristata)500 mgper 1 Vege Capsule(s)DSLD:199886
- Bucked UpBuck Naked100 mgper 3 Capsule(s)DSLD:317062
- BulkSupplements.comBerberine HCLBerberis aristata500 mgper 500 mgDSLD:310677
- BulkSupplements.comBerberine HCLBerberis aristata500 mgper 500 mgDSLD:310678
- BulkSupplements.comBerberine HCLBerberis aristata500 mgper 500 mgDSLD:310679
- BulkSupplements.comBerberine HCLBerberis aristata500 mgper 500 mgDSLD:310680
- BulkSupplements.comBerberine HCLBerberis aristata500 mgper 500 mgDSLD:310681
- BulkSupplements.comBerberine HCLBerberis aristata500 mgper 500 mgDSLD:310682
- BulkSupplements.comBerberine HCl Powder 500 mgBerberis aristata500 mgper 500 mgDSLD:330362
- BulkSupplements.comBerberine HCl Powder 500 mgBerberis aristata500 mgper 500 Milligram(s)DSLD:330366
- BulkSupplements.comBerberine HCL Powder 500 mgBerberis aristata500 mgper 500 mgDSLD:330361
- BulkSupplements.comBerberine HCL Powder 500 mgBerberis aristata500 mgper 500 mgDSLD:330363
- BulkSupplements.comBerberine HCL Powder 500 mgBerberis aristata500 mgper 500 mgDSLD:330364
- BulkSupplements.comBerberine HCL Powder 500 mgBerberis aristata500 mgper 500 Milligram(s)DSLD:330365
- CarlsonBerberine 500 mgBerberis aristata500 mgper 1 Capsule(s)DSLD:337481
- CarotecBlood Sugar SupportBerberine Phospholipids Complex550 mgper 2 Capsule(s)DSLD:320966
- CelebrateMeta GCDihydroberberine100 mgper 1 Capsule(s)DSLD:337085
- Chiro-ZymeT8 To T10 Lvr78 mgper 2 Capsule(s)DSLD:176464
- CleanCleanse SupplementsBerberine HCL Note: Berberine from Phellodendron amurense bark extract.200 mgper 1 Packet(s)DSLD:34827
- CodeageGLP-Advantage+Indian Barberry Root Extract457 mgper 2 Capsule(s)DSLD:333409
- CondemnedHumaslin500 mgper 3 Capsule(s)DSLD:335660
- Core NutritionalsBLAZEDihydroberberine100 mgper 3 Capsule(s)DSLD:297971
- Core NutritionalsMULTI150 mcgper 4 Capsule(s)DSLD:218270
- Core NutritionalsMULTI150 mgper 4 Capsule(s)DSLD:298251
- CymbiotikaMetabolic HealthDihydroberberine150 mgper 3 Vegetarian Capsule(s)DSLD:336114
- D'Adamo Personalized NutritionEl DoradoBerberis aristata100 mgper 1 Vegetarian Capsule(s)DSLD:287135
- DaVinci LaboratoriesBerberine ForceBerberine Hydrochloride500 mgper 1 Capsule(s)DSLD:338002
- DaVinci LaboratoriesMetabolic Multi100 mgper 6 Capsule(s)DSLD:313228
- DCBerberine-500500 mgper 3 Capsule(s)DSLD:331325
- Designs for HealthGI Microb-XBerberis aristata · Berberine Sulfate (Form: from Berberis aristata PlantPart: root Genus: Berberis Species: aristata)100 mgper 1 Capsule(s)DSLD:22997
- Divine HealthCarb Assist500 mgper 1 Capsule(s)DSLD:331363
- Doctors' PreferredBerberineBerberine Hydrochloride500 mgper 1 Capsule(s)DSLD:322433
- Doctors' PreferredGlucoGold with BerberineBerberine Hydrochloride500 mgper 3 Tablet(s)DSLD:309891
- Doctors' PreferredGlucoGold with BerberineBerberine Hydrochloride500 mgper 1 Tablet(s)DSLD:316987
- DoNotAge.orgPure BerberineTotal e30g1 Gram(s)per 2 Capsule(s)DSLD:315484
- Double Wood SupplementsBerberine 500 mg500 mgper 1 Capsule(s)DSLD:255568
- Double Wood SupplementsBerberine 500 mg500 mgper 1 Capsule(s)DSLD:315592
- Douglas LaboratoriesBerberine BalanceBerberis aristata extract · Berberine HCl (Form: from Berberis aristata extract PlantPart: root Genus: Berberis Species: aristata)500 mgper 1 Vegetarian CapsulesDSLD:231853
- Douglas LaboratoriesGlucoQuenchBerberis aristata extract · Berberine HCl (Form: from Berberis aristata extract PlantPart: root Genus: Berberis Species: aristata)125 mgper 2 Capsule(s)DSLD:232971
- Douglas LaboratoriesMood Systems Balance250 mgper 2 Vegetarian Capsule(s)DSLD:232761
- Douglas LaboratoriesMood Systems Balance250 mgper 2 Vegetarian Capsule(s)DSLD:261903
- Douglas LaboratoriesMood Systems Balance250 mgper 2 Vegetarian Capsule(s)DSLD:273715
- Douglas LaboratoriesUltra MFP ForteBerberis aristata · Berberine HCl (Form: from Berberis aristata CorrectedName: Berberis aristata PlantPart: Root Genus: Berberis Species: aristata)400 mgper 4 Vegetarian CapsulesDSLD:232281
- Dr. BergBlood Sugar Support Advanced Formula75 mgper 1 Capsule(s)DSLD:292024
- Dr. Clark StoreFungal Fighter 400 mg50 mgper 1 Capsule(s)DSLD:219854
- Dr. MercolaBerberine and MicroPQQ AdvancedAmur Cork Tree500 mgper 1 Capsule(s)DSLD:327144
- Dr. Seth's Vitamin VibrationsPower Blood-SugarBerberine Hydrochloride500 mgper 1 Capsule(s)DSLD:315783
- Dr. Seth's Vitamin VibrationsPower Candida-Cleanse200 mgper 3 Capsule(s)DSLD:315786
- Dr. Stephanie'sCarb & Sugar BlockerPhellodendron amurense435 mgper 1 Capsule(s)DSLD:318639
- Dr. WhitakerBerberine+ GlucoDefense500 mgper 1 Tablet(s)DSLD:178429
- Dr. WhitakerBerberine+ GlucoDefense500 mgper 1 Tablet(s)DSLD:178443
- DrFormulasBlood Sugar Support502.5 mgper 1 Packet(s)DSLD:295246
- Earthborn ElementsBerberineHydrastis canadensis1,440 mgper 3 Capsule(s)DSLD:319459
- Ee Essential elementsGluControlIndian Barberry bark extract500 mgper 2 Capsule(s)DSLD:310250
- EmmaEmmaBerberis aristata extract200 mgper 2 Capsule(s)DSLD:312631
- EnhancedSlinBerberis aristata500 mgper 4 Capsule(s)DSLD:321440
- EnzymedicaBerberineBerberis aristata510 mgper 1 Capsule(s)DSLD:296456
- EnzymedicaBerberineBerberis aristata · 95%510 mgper 1 Capsule(s)DSLD:328873
- EnzymedicaBerberine PhytosomeBerberine Phytosome · standardized to contain 28%-34% of berberine275 mgper 1 Capsule(s)DSLD:328874
- ETST Earth Science TechPain Management2.5 mgper 1 Capsule(s)DSLD:70546
- EuroMedicaBerberine 500 mgIndian Barberry Bark, Root Extract500 mgper 1 Capsule(s)DSLD:261450
- EuroMedicaBerberine Ultra AbsorbIndian Barberry Bark, Root Extract250 mgper 1 Capsule(s)DSLD:261422
- EuroMedicaBerberine Ultra AbsorptionIndian Barberry Bark, Root Extract250 mgper 1 Capsule(s)DSLD:299486
- EvogenEvologDihydroberberine84 mgper 1 Capsule(s)DSLD:264850
- eXplicit SupplementsExtra Strength Berberine 1200 mgBerberis aristata1,200 mgper 2 Capsule(s)DSLD:310031
- FINAFLEXBerberine1,000 mgper 2 Capsule(s)DSLD:333636
- FortifyCarb Regulator500 mgper 1 Capsule(s)DSLD:283912
- Foster RegalBerberine +500 mgper 1 Capsule(s)DSLD:260295
- Genestra BrandsPEA Neuro SupportBerberine Hydrochloride60 mgper 3 Capsule(s)DSLD:291744
- Good StateBerberine400 mgper 1 Capsule(s)DSLD:228953
- Good StateBerberine HCL 400 mg400 mgper 1 Capsule(s)DSLD:276979
- Good StateBerberine HCL 500 mg500 mgper 1 Capsule(s)DSLD:310819
- Good StateGlyco-X 250250 mgper 1 Capsule(s)DSLD:229013
- Good StateGlyco-X 400400 mgper 1 Capsule(s)DSLD:229045
- Good StateGlyco-X 400400 mgper 1 Capsule(s)DSLD:252931
- Good StateGlyco-X 400400 mgper 1 Capsule(s)DSLD:276934
- Good StateGlyco-X 500500 mgper 1 Capsule(s)DSLD:277904
- Greens First LeanNatural Energy160 mgper 1 Veggie Capsule(s)DSLD:312855
- Gundry MDTotal RestoreBerberine HCl · Berberine (Form: 97% Berberine HCl, Phellodendron amurense bark powder PlantPart: bark Genus: Phellodendron Species: amurense)3 mgper 3 Capsule(s)DSLD:210836
- Happy MammothHormone Harmony6:1150 mgper 3 Capsule(s)DSLD:288160
- Health Thru NutritionBerberine 500 mgby HPLC500 mgper 1 Vegicap(s)DSLD:304823
- Health Thru NutritionBerberine 500 mgby HPLC500 mgper 1 Vegecap(s)DSLD:304824
- Health Thru NutritionBerberine HCl 500 mg500 mgper 1 Vege Capsule(s)DSLD:229720
- Health Thru NutritionGlucoPro MaxBerberis aristata1,500 mgper 1 Tablet(s)DSLD:316642
- Health Thru NutritionGlucoPro Max 1500 mgBerberis aristata1,500 mgper 1 Tablet(s)DSLD:316641
- Health Thru Nutrition NaturallyBerberine HCl 500 mg500 mgper 1 Vegetarian Capsule(s)DSLD:229692
- Healths HarmonyBerberine HCL+1,000 mgper 2 Capsule(s)DSLD:318351
- HerbadietBerberine HCLBerberis aristata, Powder · Standardized to contain min 98% Berberine HCL300 mgper 1 Capsule(s)DSLD:293642
- Herbal NutritionBerberine Complex1,000 mgper 2 Vegetable Capsule(s)DSLD:317373
- Herbal SecretsBerberine 500 mg500 mgper 1 Capsule(s)DSLD:282806
- Herbs SRAGlucoSupport+Berberine Hydrochloride120 mgper 2 Capsule(s)DSLD:316174
- HoltraCeuticalsCandinex80 mgper 2 Capsule(s)DSLD:270857
- HoltraCeuticalsChol-Less Max900 mgper 3 Capsule(s)DSLD:19374
- HoltraCeuticalsChol-Less Max KOBerberine Hydrochloride · 97% Berberine Hydrochloride500 mgper 4 Capsule(s)DSLD:271471
- HoltraCeuticalsGlucorol1 Gram(s)per 3 Capsule(s)DSLD:270814
- HoltraCeuticalsGlucorol SX1,000 mgper 3 Capsule(s)DSLD:19388
- HoltraCeuticalsPara X75 mgper 1 Capsule(s)DSLD:273785
- Huge NutritionUtilize1.5 Gram(s)per 3 Capsule(s)DSLD:299816
- IF Intestinal FortitudeAI-5500 mgper 3 Vegetarian Capsule(s)DSLD:229792
- IN.FORM Nature's SunshineMetabolic Age Support BerberineIndian Barberry · Berberine (Form: from Indian Barberry PlantPart: root Genus: Berberis Species: artistata)333 mgper 1 Capsule(s)DSLD:207891
- INNOSUPPSInno Shred GLP-1200 mgper 2 Capsule(s)DSLD:331213
- INNOSUPPSTrim Biome GLP-1400 mgper 2 Capsule(s)DSLD:332841
- InnovaPharm EssentialsBerberine X5Dihydroberberine100 mgper 1 Capsule(s)DSLD:299145
- Integrative TherapeuticsBerberine500 mgper 1 Capsule(s)DSLD:269636
- Integrative TherapeuticsBerberine500 mgper 1 Capsule(s)DSLD:269858
- Integrative TherapeuticsBerberine500 mgper 1 Capsule(s)DSLD:336409
- Integrative TherapeuticsBerberine500 mgper 1 Capsule(s)DSLD:336410
- Integrative TherapeuticsPara-Gard450 mgper 1 Capsule(s)DSLD:251196
- Integrative TherapeuticsPara-Gard450 mgper 1 Capsule(s)DSLD:251179
- Iron Brothers SupplementsLiver Support100 mgper 2 Capsule(s)DSLD:317910
- Justified LaboratoriesBlood Balance MaxBarberry50 mgper 2 Capsule(s)DSLD:276014
- Justified LaboratoriesBlood Balance MaxBarberry50 mgper 1 Capsule(s)DSLD:315890
- Justified LaboratoriesGlucofort MaxBarberry50 mgper 1 Capsule(s)DSLD:276409
- Justified LaboratoriesGlucofort MaxBarberry50 mgper 1 Capsule(s)DSLD:341031
- Justified LaboratoriesGlucotrust MaxBarberry50 mgper 1 Capsule(s)DSLD:315926
- Justified LaboratoriesPure Synapse XT MaxBarberry50 mgper 1 Capsule(s)DSLD:276448
- Justified LaboratoriesResveratrol MaxBarberry50 mgper 1 Capsule(s)DSLD:316001
- Justified LaboratoriesSweet Relief Glycogen Support ExtremeBarberry50 mgper 2 Capsule(s)DSLD:341387
- Justified LaboratoriesVisiClear MaxBarberry50 mgper 1 Capsule(s)DSLD:276462
- JuvenonYouthful Metabolism500 mgper 2 Capsule(s)DSLD:50107
- KaraMDVital Restore500 mgper 3 Veggie Capsule(s)DSLD:243837
- LegionBalanceBerberis aristata1,500 mgper 5 Capsule(s)DSLD:248774
- LES LabsInsulin Health250 mgper 1 Capsule(s)DSLD:276519
- LifeSeasons EssentialsBerberine HCL 1000 mgPhellodendron amurense Root Extract1,000 mgper 3 Capsule(s)DSLD:310463
- Like A Pro SupplementsAnytime Burn V4Dihydroberberine100 mgper 2 Capsule(s)DSLD:335648
- Like A Pro SupplementsBurn Away V3Dihydroberberine100 mgper 2 Capsule(s)DSLD:320086
- LiveGoodLean 8Berberis aristata · Berberine Hydrochloride 97%200 mgper 2 Capsule(s)DSLD:333593
- Logos NutritionalsFitcose 1CPhellodendron amurense1,000 mgper 1 Capsule(s)DSLD:335711
- Longevity PremierGlucose Formula500 mgper 2 Veggie Capsule(s)DSLD:277539
- Longevity PremierGlucose Formula500 mgper 2 Veggie Capsule(s)DSLD:278161
- longlifenutriBerberine 500 mg500 mgper 1 Vegetarian Capsule(s)DSLD:313661
- Loomis EnzymesLvr78 mgper 2 Capsule(s)DSLD:177269
- LuckyVitaminBerberine 400 mgBerberis aristata400 mgper 1 Softgel(s)DSLD:283107
- Luma NutritionBerberine 1200 mgBerberis aristata1,200 mgper 2 Capsule(s)DSLD:299463
- MegaFoodBerberine PhytosomeBerberine Phytosome550 mgper 1 Capsule(s)DSLD:333191
- Mental RefreshmentBerberine HCl 900 mgBerberis aristata900 mgper 2 Capsule(s)DSLD:321773
- MetagenicsBerberine GTPhellodendron amurense bark extract500 mgper 1 Vegetarian Capsule(s)DSLD:323329
- MetagenicsCandiBactin-BRPhellodendron amurense bark extract · Berberine from Phellodendron amurense bark extract.400 mgper 2 Tablet(s)DSLD:295644
- MetagenicsCandiBactin-BRBerberine400 mgper 2 Tablet(s)DSLD:323058
- MetagenicsCandiBactin-BRBerberine400 mgper 2 Tablet(s)DSLD:327630
- MetagenicsCandiBactin-BRBerberine400 mgper 2 Tablet(s)DSLD:327631
- MetagenicsOsteraPhellodendron amurense bark extract90 mgper 1 Tablet(s)DSLD:295850
- MetagenicsWellness Essentials Women's PrimePhellodendron amurense bark extract180 mgper 1 Packet(s)DSLD:216515
- MilaMiAmorBerberine Complex500 mgper 1 Capsule(s)DSLD:331946
- Morphogen NutritionMorphoprime1,000 mgper 6 Capsule(s)DSLD:212817
- Moss NutritionParaBotanic Select200 mgper 4 Capsule(s)DSLD:306497
- MTS NutritionNutrient DriverPhellodendron amurense750 mgper 2 Capsule(s)DSLD:323116
- Natural FactorsWellBetX Berberine 500 mgBerberine Hydrochloride500 mgper 1 Vegetarian Capsule(s)DSLD:183385
- Natural FactorsWellBetX Berberine 500 mgBerberine Hydrochloride500 mgper 1 Vegetarian Capsule(s)DSLD:76208
- Nature's CraftBerberine Advanced Complex1,000 mgper 2 Vegetable Capsule(s)DSLD:296639
- Nature's SunshineBerberineIndian Barberry333 mgper 1 Veg Cap(s)DSLD:255156
- Nature's SunshineDetox BasicsIndian Barberry1,000 mgper 1 Packet(s)DSLD:313084
- Nature's TruthBerberine 500 mgBarberry extract500 mgper 2 Vegetarian Capsule(s)DSLD:306634
- NatureCityTrueGlucoSPDihydroberberine100 mgper 1 Capsule(s)DSLD:320931
- Natures Plus KetoLivingSugar ControlBerberine Note: from750 mgper 3 Capsule(s)DSLD:250118
- NeurobiologixBerberine 500 mgAmur Cork Tree500 mgper 2 Capsule(s)DSLD:299485
- New SunAdvanced IN-F PlusBerberis aristata Root Extract5 mgper 1 Veg Capsule(s)DSLD:313653
- NewtonEverettSuperFlex-3 Advanced2.5 mgper 1 Packet(s)DSLD:213177
- NFHBerberine SAPBerberis aristata271.5 mgper 1 Capsule(s)DSLD:273283
- NHC Natural Healthy ConceptsCardioMetabolic Health Formula1 Gram(s)per 3 Capsule(s)DSLD:318477
- Nootropics DepotBerberine HCL Capsules 380 mg760 mgper 2 Capsule(s)DSLD:232063
- Nootropics DepotBerberine HCL Powder500 mgper 500 mgDSLD:232061
- Nova NutritionsBerberine Plus 1000 mg1,000 mgper 2 Capsule(s)DSLD:229218
- NOWBerberine Glucose SupportBerberis aristata400 mgper 1 Softgel(s)DSLD:313585
- NOWD-FlameBerberis aristata root extract · Berberine (Form: from Berberis aristata root extract PlantPart: root Genus: Berberis Species: aristata)5 mgper 1 Veg Capsule(s)DSLD:245748
- NuMedicaBerberine VasoQXBerberis aristata Bark Extract400 mgper 1 Capsule(s)DSLD:326164
- Nutra HarmonyResveratrol Berberine Quercetin Apple Cider Vinegar Acai & NoniBerberis aristata Extract · 20:1 extract75 mgper 2 Capsule(s)DSLD:336265
- NutraBeticBerberine+Dihydroberberine · equivalent to 1200 mg berberine240 mgper 2 Capsule(s)DSLD:327458
- NutraBeticBerberine+Dihydroberberine · equivalent to 1200 mg berberine240 mgper 2 Capsule(s)DSLD:327459
- NutraBioBerberine AdvancedDihydroberberine200 mgper 1 Vegetarian Capsule(s)DSLD:318065
- NutranizeZone MorningIndian Barberry root extract30 mgper 2 Capsule(s)DSLD:335604
- NutriCologyGlucevia Complex with Chromium500 mgper 2 Capsule(s)DSLD:235557
- NutriCologyTriBiotics400 mgper 1 Capsule(s)DSLD:234808
- NutriCologyTriBiotics400 mgper 1 Capsule(s)DSLD:234809
- NutricostBerberine 1,200 mgBerberis aristata1,200 mgper 2 Capsule(s)DSLD:316999
- NutriFlairCeylon Cinnamon + Berberine & ChromiumBerberis aristata200 mgper 2 Capsule(s)DSLD:299688
- NutriONNBerberine1,200 mgper 2 Veggie Capsule(s)DSLD:308882
- NutriveinPremium Berberine+ Plus 1200 mgBerberis aristata Bark Extract · 10:11,200 mgper 2 Capsule(s)DSLD:334806
- NutriveinPremium Berberine+ Plus1200 mg Extra Strength1,200 mgper 2 Vegetable Capsule(s)DSLD:243548
- Ormus MineralsBlood Sugar Stabilizer99%amount not statedper 4 Capsule(s)DSLD:269136
- Ortho Molecular ProductsCandicid Forte150 mgper 2 Capsule(s)DSLD:173999
- Ortho Molecular ProductsCandicid Forte150 mgper 2 Capsule(s)DSLD:174001
- Ortho Molecular ProductsCardio Met Pack1 Gram(s)per 1 Pack(s)DSLD:270259
- Ortho Molecular ProductsCystistatin200 mgper 1 Capsule(s)DSLD:174721
- Ortho Molecular ProductsParacid Forte75 mgper 1 Capsule(s)DSLD:175479
- Ortho Molecular ProductsPyloricil150 mgper 1 Capsule(s)DSLD:174564
- Ortho Molecular ProductsSinatrol100 mgper 3 Capsule(s)DSLD:175342
- Ortho Molecular ProductsSinatrol100 mgper 3 Capsule(s)DSLD:175354
- Patient One 1 MediNutritionalsBerberine 500 mgIndian Barberry extract · Berberine HCl (Form: from Indian Barberry extract PlantPart: root Genus: Berberis Species: aristata)500 mgper 1 Capsule(s)DSLD:276247
- Priority One Nutritional SupplementsDiamendCoptis chinensis Root Extract · 97%600 mgper 3 Tablet(s)DSLD:310766
- Priority One Nutritional SupplementsSIBOticCoptis chinensis Root Extract · 97% extract500 mgper 6 Vegetarian Capsule(s)DSLD:310782
- ProCapsBerberine Phospholipid ComplexBerberis aristata Root Extract · standardized to 28%-34% Berberine1,100 mgper 1 Capsule(s)DSLD:331516
- ProCapsImmune FactorsBerberis spp. Root Extract60 mgper 2 Capsule(s)DSLD:331566
- ProCaps LaboratoriesBerberine 250Berberis spp. Root Extract250 mgper 1 Capsule(s)DSLD:320061
- Protocol For Life BalanceD-FlameBerberis aristata root extract · Berberine (Form: from Berberis aristata root extract PlantPart: root Genus: Berberis Species: aristata)5 mgper 1 Veg Capsule(s)DSLD:77418
- Protocol For Life BalanceGlucose Management With Berberine HClBerberis aristata · Berberine HCl (Form: from Berberis aristata PlantPart: bark Genus: Berberis Species: aristata)400 mgper 1 Softgel(s)DSLD:73468
- Protocol For Life BalanceGlucose Management With Berberine HClBerberis aristata · Berberine HCl (Form: from Berberis aristata PlantPart: bark Genus: Berberis Species: aristata)400 mgper 1 Softgel(s)DSLD:73803
- Pure EncapsulationsA.C. Formula II50 mgper 2 Capsule(s)DSLD:293871
- Pure EncapsulationsCholestePure PlusBerberine Phytosome · standardized to contain 28% berberine, sunflower phospholipid complex275 mgper 2 Capsule(s)DSLD:299745
- Pure EncapsulationsCholestePure PlusBerbevis · standardized to contain 28% berberine275 mgper 2 Capsule(s)DSLD:299746
- Pure EncapsulationsCholestePure Plus ll400 mgper 2 Capsule(s)DSLD:183999
- Pure EncapsulationsCholestePure Plus ll400 mgper 2 Capsule(s)DSLD:293932
- Pure EncapsulationsEndoLOX150 mgper 1 Capsule(s)DSLD:185288
- Pure EncapsulationsMetabolic Xtra350 mgper 1 Capsule(s)DSLD:246350
- Pure EncapsulationsMetabolic Xtra350 mgper 1 Capsule(s)DSLD:287431
- Pure EncapsulationsMetabolic Xtra350 mgper 1 Capsule(s)DSLD:294024
- Pure EncapsulationsMicroDefense100 mgper 1 Capsule(s)DSLD:184659
- Pure EncapsulationsMicroDefense100 mgper 1 Capsule(s)DSLD:185088
- Pure EncapsulationsMicroDefense w/Oregano100 mgper 1 Capsule(s)DSLD:294025
- Pure EncapsulationsMicroDefense w/Oregano100 mgper 1 Capsule(s)DSLD:295531
- Pure EncapsulationsTh1 Support500 mgper 2 Capsule(s)DSLD:299739
- PureFormulasBerberine CompleteBerberis aristata extract · Berberine HCl (Form: from Berberis aristata extract PlantPart: root Genus: Berberis Species: aristata)500 mgper 1 Vegetarian Capsule(s)DSLD:228419
- PureFormulasCandiEradBerberine HCl400 mgper 4 Capsule(s)DSLD:278951
- PureHealth ResearchBlood Sugar FormulaBerberis aristata extract100 mgper 3 Vegetarian Capsule(s)DSLD:257684
- PureHealth ResearchKidney HealthIndian Barberry bark extract100 mgper 2 Capsule(s)DSLD:310961
- Purely OptimalBerberineBerberis aristata1,200 mgper 2 Capsule(s)DSLD:295273
- Puritan's PrideBerberine 1,000 mg & Silymarin 200 mgBerberis aristata1,000 mgper 2 Capsule(s)DSLD:286414
- Puritan's PrideBerberine 500 mgBerberis aristata500 mgper 1 Capsule(s)DSLD:286416
- Puritan's PrideBerberine 500 mg Alpha Lipoic Acid 400 mg Grape Seed 100 mg500 mgper 3 Capsule(s)DSLD:286413
- PurusShuttle500 mgper 4 Capsule(s)DSLD:326491
- Q-Leap NutraceuticalsGlucoquell200 mgper 1 Capsule(s)DSLD:308307
- Renew LifeCandi Smart 125 mgper 1 Capsule(s)DSLD:178861
- Renew LifeCandi Smart 125 mgper 2 Capsule(s)DSLD:247375
- Renew LifeCandiSmart 125 mgper 2 Capsule(s)DSLD:250745
- Renue By ScienceCardioMAXLiposomal100 mgper 2 Vegetarian Capsule(s)DSLD:318988
- Renue By ScienceLipo Berberine150 mgper 1 Vegetarian Capsule(s)DSLD:319015
- Reset/360Support TeamBerberine HCL Note: Berberine from Phellodendron amurense bark extract.400 mgper 2 Tablet(s)DSLD:249346
- Rich Piana 5% NutritionFreak ShowPhellodendron amurense350 mgper 3 Capsule(s)DSLD:333959
- S.O LabsAltai Balance148 mgper 2 Capsule(s)DSLD:257641
- S.O LabsGluconite148 mgper 2 Capsule(s)DSLD:257816
- SigmaCeuticalKnee, Hip & Joint Complex2.5 mgper 1 Capsule(s)DSLD:255964
- Signature SupplementsBerberineIndian Barberry Root Extract400 mgper 2 Capsule(s)DSLD:338613
- Signature SupplementsBlood Sugar BalanceIndian Barberry250 mgper 2 Capsule(s)DSLD:338619
- Signature SupplementsDiabetic BalanceIndian Barberry250 mgper 2 Capsule(s)DSLD:338673
- Signature SupplementsUTI Clear200 mgper 2 Capsule(s)DSLD:338966
- Simple-OrganicsBerberine 1000 mg1,000 mgper 2 Capsule(s)DSLD:271580
- Simple-OrganicsBerberine 1000 mg1,000 mgper 2 Capsule(s)DSLD:316997
- Simply Natures PureBerberineBerberis aristata500 mgper 1 Capsule(s)DSLD:323393
- SolarayBerberine & Curcumin Root ExtractsIndian Barberry root extract300 mgper 1 VegCap(s)DSLD:295998
- SolarayBerberine 500 mgIndian Barberry Root Extract500 mgper 1 VegCap(s)DSLD:295999
- SolarayBerberine PhytosomeBerberine Phytosome · standardized to 30% Berberine HCl550 mgper 1 VegCap(s)DSLD:338216
- SolarayBerberine with Oregon GrapeIndian Barberry Root Extract250 mgper 1 VegCap(s)DSLD:325916
- SolarayBergamot 500 mgIndian Barberry Root Extract130 mgper 2 VegCap(s)DSLD:296000
- SolarayBergamot 500 mgIndian Barberry Root Extract130 mgper 2 VegCap(s)DSLD:339076
- SolarayImmufight Immune Response SupportIndian Barberry root extract100 mgper 3 VegCap(s)DSLD:325993
- SolarayImmufight Respiratory SupportIndian Barberry extract100 mgper 3 VegCap(s)DSLD:255555
- Source NaturalsBerberine 500 mgBerberis aristata · Berberine HCl (Form: from Berberis aristata CorrectedName: Berberis aristata PlantPart: Root Genus: Berberis Species: aristata)500 mgper 1 Vegetarian Capsule(s)DSLD:217105
- Source NaturalsBerberine 500 mgBerberis aristata · Berberine HCl (Form: from Berberis aristata CorrectedName: Berberis aristata PlantPart: Root Genus: Berberis Species: aristata)500 mgper 1 Vegetarian Capsule(s)DSLD:217107
- Spring ValleyBerberine 1200 mg1,200 mgper 2 Capsule(s)DSLD:331631
- SunergeticBerberine 1200 mgBerberis aristata extract1,200 mgper 2 Capsule(s)DSLD:276813
- SuperBonsaiSuper LiverBerberis aristata Bark Extract · 10:183 mgper 2 mLDSLD:339378
- SuperSmartBerberine 1000 mg1,000 mgper 2 Capsule(s)DSLD:315521
- SuperSmartLongevity Nutrients350 mgper 4 Capsule(s)DSLD:332392
- SwansonBerberine 400 mg400 mgper 1 Capsule(s)DSLD:265026
- SwansonBerberine ComplexBerberis aristata · Berberine HCl (Form: from Berberis aristata CorrectedName: Berberis aristata PlantPart: Root Genus: Berberis Species: aristata)150 mgper 1 Veggie Capsule(s)DSLD:203168
- SwansonPure Blood Sugar400 mgper 2 Veggie Capsule(s)DSLD:257775
- Terry NaturallyBerberine MetXIndian Barberry Bark, Root Extract250 mgper 1 Capsule(s)DSLD:304492
- Terry NaturallyBerberine MetX 500 mgIndian Barberry Bark Extract500 mgper 1 Capsule(s)DSLD:325721
- ThorneBerberineIndian Barberry extract200 mgper 1 Capsule(s)DSLD:298058
- ThorneBerberineIndian Barberry Root Extract450 mgper 1 Capsule(s)DSLD:328820
- ThorneBerberine 200 mgIndian Barberry extract200 mgper 1 Capsule(s)DSLD:336355
- ThorneLiver CleanseIndian Barberry extract · Berberine HCl (Form: from Indian Barberry extract PlantPart: root Genus: Berberis Species: aristata)125 mgper 1 Capsule(s)DSLD:336357
- ThrivousVitality Geroprotector500 mgper 4 Capsule(s)DSLD:206256
- Triquetra Rx TherapeuticsGLP-ActivateBerberis aristata Root Extract · 40:1 ratio195 mgper 1 Capsule(s)DSLD:338464
- Troponin SupplementsSuppressor MaxBerberis aristata · 97%1,500 mgper 7 Capsule(s)DSLD:320868
- True BotanicaBerberine Plus500 mgper 2 Capsule(s)DSLD:336204
- UNBOUNDSLYNDihydroberberine200 mgper 6 Capsule(s)DSLD:329463
- VEGATOTOrganic Berberine ComplexBerberis aristata Extract · 15:1 Extract400 mgper 1 Capsule(s)DSLD:317002
- Vita LogicInflama FreeBerberine Sulfate · Berberine (Form: as Berberine Sulfate, from Indian Barberry root extract PlantPart: root) PlantPart: root79 mgper 2 Vegetarian Capsule(s)DSLD:248177
- VitabasePain RX2.5 mgper 2 Capsule(s)DSLD:6209
- Vital NutrientsBerberine 200 mgBerberis aristata · Berberine (Form: extracted from Berberis aristata PlantPart: root Genus: Berberis Species: aristata)400 mgper 1 Vegetarian Capsule(s)DSLD:207046
- Vital NutrientsBerberine 200 mgBerberis aristata · standardized to 97% berberine200 mgper 1 Vegetarian Capsule(s)DSLD:304948
- Vital NutrientsBerberine 500 mg1,000 mgper 1 Vegetarian Capsule(s)DSLD:304949
- Vital NutrientsGoldenseal PlusBerberine HCl64 mgper 1 Vegetarian CapsulesDSLD:72003
- Vital NutrientsHerbal Biotic80 mgper 2 Vegetarian Capsule(s)DSLD:223256
- Vital NutrientsHerbal Biotic80 mgper 2 Vegetarian Capsule(s)DSLD:305052
- Vital NutrientsViraCon50 mgper 2 Vegetarian Capsule(s)DSLD:223202
- VitamaticBerberine 500 mgBerberis aristata500 mgper 1 Vegetable Capsule(s)DSLD:316998
- Vitamin Research ProductsGI Cell Support65 mgper 2 Capsule(s)DSLD:33999
- Vitamin Research ProductsKandidaPlexBerberine Sulfate · Berberine (Form: as Berberine Sulfate)50 mgper 1 Capsule(s)DSLD:34001
- VitaMonkCortiTraxPhellodendron amurense Rupr. bark extract25 mgper 2 Vegetarian Capsule(s)DSLD:242109
- VitaMonkGlucoCell200 mgper 2 Capsule(s)DSLD:242143
- VitauthorityBerberine+Dihydroberberine170 mgper 2 Capsule(s)DSLD:331355
- Whitaker NutritionBerberineBerberine Hydrochloride500 mgper 3 Capsule(s)DSLD:315951
- Whitaker NutritionBerberine GlucoGOLDBerberine Hydrochloride500 mgper 1 Tablet(s)DSLD:313214
- Whitaker NutritionBerberine GlucoGOLDBerberine Hydrochloride500 mgper 1 Tablet(s)DSLD:313215
- Whitaker NutritionBerberine GlucoGOLDBerberine Hydrochloride500 mgper 1 Tablet(s)DSLD:313216
- Wholly LiquidSpiroLazePhellodendron amurense300 mgper 5 Drop(s)DSLD:272132
- Wonder LaboratoriesBerberine-500+ TripleDefense500 mgper 1 Capsule(s)DSLD:260782
- Wonder LabsBerberine 500 mg500 mgper 1 Capsule(s)DSLD:262337
- Wonder LabsBerberine 500 mg500 mgper 3 Capsule(s)DSLD:263010
- Wonder LabsBerberine 500 mg500 mgper 1 Capsule(s)DSLD:299484
- Wonder LabsBerberine 500 mg500 mgper 1 Capsule(s)DSLD:325836
- Wonder LabsBerberine-500+ TripleDefense500 mgper 1 Capsule(s)DSLD:256055
- XYMOGENALAmax Protect500 mgper 2 Capsule(s)DSLD:294629
- XYMOGENALAmax Protect500 mgper 2 Capsule(s)DSLD:37373
- XYMOGENBerbemycin250 mgper 2 Capsule(s)DSLD:294639
- XYMOGENBerberine1 Gram(s)per 2 Capsule(s)DSLD:303644
- XYMOGENBerberine1 Gram(s)per 2 Capsule(s)DSLD:335431
- XYMOGENBerberine 1 g1 Gram(s)per 2 Capsule(s)DSLD:258984
- XYMOGENBerberine ES-5Dihydroberberine200 mgper 1 Capsule(s)DSLD:303645
- XYMOGENBerberine with InSea2500 mgper 1 Capsule(s)DSLD:303646
- Zenith LabsBlood Sugar PremierBarberry Root Extract50 mgper 2 Capsule(s)DSLD:326179
- ZenMenH. pylori SupportBerberis aristata150 mgper 2 Veggie Capsule(s)DSLD:310005
- ZHOUBerberine 1000 mgBerberis aristata root extract1,000 mgper 2 Veggie Capsule(s)DSLD:249951
Label record: NIH Office of Dietary Supplements · CC0
Registered, and not reported
- Source
- ClinicalTrials.gov
- Intervention
- berberine
- Status
- Completed, terminated or suspended
- Results posted
- No
Trials without posted results
70 trials
70 registered trials without posted results · Overdue (FDAAA 801): 65
65 past the window5 within it, or no actual date
- NCT07480018completed2026-05-03a university or hospital
- NCT07215676completed2026-02-25a university or hospital
- NCT07359209completed2026-01-30a university or hospital
- NCT05720299completed2025-06-30a university or hospitalpast the reporting window
- NCT06415773completed2025-06-13industrypast the reporting window
- NCT06514274completed2025-04-30a university or hospitalpast the reporting window
- NCT03976336completed2025-04-01a university or hospitalpast the reporting window
- NCT06245382completed2024-12-31a university or hospitalpast the reporting window
- NCT06350890completed2024-12-12industrypast the reporting window
- NCT06353347completed2024-12-12industrypast the reporting window
- NCT06732908completed2024-08-27a university or hospitalpast the reporting window
- NCT06863922completed2024-08-14a university or hospitalpast the reporting window
Show the remaining 58
- NCT05647915completed2024-08-09a government bodypast the reporting window
- NCT06097871completed2024-07-24industrypast the reporting window
- NCT06535698completed2024-06-10industrypast the reporting window
- NCT06273241completed2024-05-11a university or hospitalpast the reporting window
- NCT06591767completed2024-04-30a university or hospitalpast the reporting window
- NCT05845931completed2023-12-31a university or hospitalpast the reporting window
- NCT06202157completed2023-12-31industrypast the reporting window
- NCT05947370completed2023-04-06a university or hospitalpast the reporting window
- NCT05480670completed2023-03-31a university or hospitalpast the reporting window
- NCT06411275completed2023-01-17industrypast the reporting window
- NCT05570357completed2023-01-01a university or hospitalpast the reporting window
- NCT05463003completed2022-11-20a university or hospitalpast the reporting window
- NCT05832463completed2022-07-12industrypast the reporting window
- NCT06187298completed2022-05-16a university or hospitalpast the reporting window
- NCT05370261completed2022-05-04industrypast the reporting window
- NCT05014334completed2022-03-31a university or hospitalpast the reporting window
- NCT04428606completed2022-03-30a university or hospitalpast the reporting window
- NCT04697186completed2021-12-20a university or hospitalpast the reporting window
- NCT02808351completed2021-12a university or hospitalpast the reporting window
- NCT03221894completed2021-07-31a university or hospitalpast the reporting window
- NCT02983188completed2020-12-30a university or hospitalpast the reporting window
- NCT05021341completed2020-11-04a university or hospitalpast the reporting window
- NCT03770325completed2020-11-01a university or hospitalpast the reporting window
- NCT03281096completed2020-10-12a university or hospitalpast the reporting window
- NCT04932070completed2020-10-06a university or hospitalpast the reporting window
- NCT03438292completed2020-09-11a university or hospitalpast the reporting window
- NCT03333265completed2020-08-31a university or hospitalpast the reporting window
- NCT04479202completed2020-04-18a research networkpast the reporting window
- NCT03972215completed2020-01-20a university or hospitalpast the reporting window
- NCT03388762completed2019-09-30a university or hospitalpast the reporting window
- NCT04107987completed2019-08-31a university or hospitalpast the reporting window
- NCT03609892completed2019-08-20a university or hospitalpast the reporting window
- NCT06703086completed2019-08-15a university or hospitalpast the reporting window
- NCT04049396completed2019-03-25a university or hospitalpast the reporting window
- NCT02226185completed2018-12-29a university or hospitalpast the reporting window
- NCT03330184completed2018-04a university or hospitalpast the reporting window
- NCT03019263completed2018-01-12a university or hospitalpast the reporting window
- NCT03470376completed2017-11-15a university or hospitalpast the reporting window
- NCT03251716completed2017-10-30a university or hospitalpast the reporting window
- NCT06426966completed2017-02-01a university or hospitalpast the reporting window
- NCT02834078completed2016-07industrypast the reporting window
- NCT02633930completed2016-06a university or hospitalpast the reporting window
- NCT03548155completed2015-12-14a university or hospitalpast the reporting window
- NCT03097965completed2015-11-20industrypast the reporting window
- NCT01697735terminated— Because of lack of participants and funds2015-09a university or hospitalpast the reporting window
- NCT02296021completed2015-09a university or hospitalpast the reporting window
- NCT02936414completed2015-08a university or hospitalpast the reporting window
- NCT02295176completed2015-03industrypast the reporting window
- NCT02422927completed2015-01a university or hospitalpast the reporting window
- NCT01293162completed2014-10a university or hospitalpast the reporting window
- NCT01696448completed2013-04industrypast the reporting window
- NCT01562080completed2012-06industrypast the reporting window
- NCT00633282completed2011-08a university or hospitalpast the reporting window
- NCT02078167completed2011-01a university or hospitalpast the reporting window
- NCT01087632completed2010-07industrypast the reporting window
- NCT00654459completed2008-01a university or hospitalpast the reporting window
- NCT00425009completedno completion datea university or hospital
- NCT00462046completedno completion datea university or hospital
Papers screened
1,475 papers
- Compound
- berberine
- Screened
- 1,475
- Admitted
- 26
- Discarded
- 1,078
- Not read
- 371
- Showing
- 200 of 1,475
Produced a finding26 papers
- PMID:375987532026-10-11
- PMID:392366622026-10-11
- PMID:282418172026-10-05
- PMID:306625842026-10-05
- PMID:313379822026-10-05
- PMID:318331072026-10-05
- PMID:323571872026-10-05
- PMID:344213582026-10-05
- PMID:218701062026-10-05
- PMID:262527772026-10-05
- PMID:276297502026-10-05
- PMID:363130962026-10-05
and 14 more.
Read and discarded1,078 papers
- PMID:11823761cited by PMID:21870106; not about the subject it would be filed under2026-10-13
- PMID:17611934cited by PMID:21870106; not about the subject it would be filed under2026-10-13
- PMID:18378963cited by PMID:21870106; not about the subject it would be filed under2026-10-13
- PMID:19361005cited by PMID:21870106; not about the subject it would be filed under2026-10-13
- PMID:19604036cited by PMID:21870106; not about the subject it would be filed under2026-10-13
- PMID:20393696cited by PMID:21870106; not about the subject it would be filed under2026-10-13
- PMID:18442638no claim extracted — within_arm_only2026-10-11
- PMID:22998978no claim extracted — comparator_not_absence2026-10-11
- PMID:26645811no claim extracted — within_arm_only2026-10-11
- PMID:35623810no claim extracted — combination_exposure2026-10-11
- PMID:36805484no claim extracted — comparator_not_absence2026-10-11
- PMID:37183391no claim extracted — combination_exposure2026-10-11
and 1,066 more.
Not read yet371 papers
- PMID:183558292026-10-09
- PMID:205670262026-10-09
- PMID:219153472026-10-09
- PMID:240061932026-10-09
- PMID:208366202026-10-06
- PMID:220025962026-09-29
- PMID:247289532026-09-29
- PMID:320707672026-09-29
- PMID:322838822026-09-29
- PMID:350635792026-09-29
- PMID:353826952026-09-29
- PMID:357845462026-09-29
and 359 more.
Measured, not recorded
- Compound
- berberine
- Endpoints measured
- 1,319 endpoints
- Recorded as a finding
- No
Show what was measured
Fasting blood glucose
decreases, p = 0.01
fasting blood glucose (from 10.6+/-0.9 mmol/L to 6.9+/-0.5 mmol/L, P<.01)
PMID:18442638 · one of two readings recorded this
HOMA-IR
decreases, p = 0.001
Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively
PMID:18442638 · one of two readings recorded this
Fasting and postprandial blood glucose
decreases
Berberine acted by lowering fasting blood glucose and postprandial blood glucose from 1 week to the end of the trial
PMID:18442638 · one of two readings recorded this
Fasting plasma insulin
decreases, p = 0.001
Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively
PMID:18442638 · one of two readings recorded this
hemoglobin A1c, fasting blood glucose, postprandial blood glucose, plasma triglycerides, fasting insulin and HOMA-IR before and after 3 months of berberine
decreases, HbA1c from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01, within the berberine group
Not recorded as a finding: the result compares a group with itself, not with a control
Significant decreases in hemoglobin A1c (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01), fasting blood glucose (from 10.6+/-0.9 mmol/L to 6.9+/-0.5 mmol/L, P<.01), postprandial blood glucose (from 19.8+/-1.7 to 11.1+/-0.9 mmol/L, P<.01), and plasma triglycerides (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05) were observed in the berberine group.
PMID:18442638 · one of two readings recorded this
hemoglobin A1c, fasting blood glucose, postprandial glucose, plasma triglycerides in type 2 diabetes
decreases, 8.1% to 7.3% (study B, berberine-supplemented patients, no control arm)
Not recorded as a finding: the result compares a group with itself, not with a control
Hemoglobin A1c decreased from 8.1%+/-0.2% to 7.3%+/-0.3% (P<.001).
PMID:18442638 · one of two readings recorded this
Hemoglobin A1c
decreases, p = 0.01
hemoglobin A1c (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01)
PMID:18442638 · one of two readings recorded this
Hemoglobin A1c
decreases, p = 0.001
Hemoglobin A1c decreased from 8.1%+/-0.2% to 7.3%+/-0.3% (P<.001)
PMID:18442638 · one of two readings recorded this
Hypoglycemic effect, berberine versus metformin
no effect
The hypoglycemic effect of berberine was similar to that of metformin
PMID:18442638 · one of two readings recorded this
Plasma triglycerides
decreases, p = 0.05
plasma triglycerides (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05)
PMID:18442638 · one of two readings recorded this
Postprandial blood glucose
decreases, p = 0.01
postprandial blood glucose (from 19.8+/-1.7 to 11.1+/-0.9 mmol/L, P<.01)
PMID:18442638 · one of two readings recorded this
Total cholesterol and LDL cholesterol
decreases
Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well
PMID:18442638 · one of two readings recorded this
CYP2C9 activity, 0–8 h losartan/E-3174 ratio
increases, p = 0.01, n = 17
losartan/E-3174 ratio doubled (P<0.01) after BBR administration, indicating a decrease in CYP2C9 activity
PMID:21870106 · one of two readings recorded this
CYP2D6 activity, 0–8 h urinary dextromethorphan/dextrorphan ratio
increases, p = 0.01, n = 17
A decrease in CYP2D6 activity was observed as the 0–8 h urinary dextromethorphan/dextrorphan ratio increased ninefold (P<0.01)
PMID:21870106 · one of two readings recorded this
Midazolam AUC0–12
increases, p = 0.05, n = 17
CYP3A4 activity was also inhibited, as the Cmax, AUC0–∞, and AUC0–12 of mid-azolam were increased 38% (P<0.05), 40% (P<0.01), and 37% (P<0.05) after BBR treatment
PMID:21870106 · one of two readings recorded this
Midazolam AUC0–∞
increases, p = 0.01, n = 17
CYP3A4 activity was also inhibited, as the Cmax, AUC0–∞, and AUC0–12 of mid-azolam were increased 38% (P<0.05), 40% (P<0.01), and 37% (P<0.05) after BBR treatment
PMID:21870106 · one of two readings recorded this
Midazolam Cmax
increases, p = 0.05, n = 17
CYP3A4 activity was also inhibited, as the Cmax, AUC0–∞, and AUC0–12 of mid-azolam were increased 38% (P<0.05), 40% (P<0.01), and 37% (P<0.05) after BBR treatment
PMID:21870106 · one of two readings recorded this
Midazolam oral clearance
decreases, p = 0.05, n = 17
the oral clearance of midazolam was decreased 27% (P<0.05)
PMID:21870106 · one of two readings recorded this
Midazolam T1/2
increases, n = 17
Compared with the placebo period, the Tmax and T1/2 of midazolam during BBR administration were prolonged from 3.03±0.27 to 3.66± 0.37 h and 0.66±0.08 to 0.99±0.09 h, respectively
PMID:21870106 · one of two readings recorded this
Midazolam Tmax
increases, n = 17
Compared with the placebo period, the Tmax and T1/2 of midazolam during BBR administration were prolonged from 3.03±0.27 to 3.66± 0.37 h and 0.66±0.08 to 0.99±0.09 h, respectively
PMID:21870106 · one of two readings recorded this
Pharmacokinetic parameters of other probe drugs (omeprazole CYP2C19, caffeine CYP1A2)
no effect, n = 17
There were no statistically significant differences in the pharmacokinetic parameters of the other probe drugs between placebo and the BBR-treated group
PMID:21870106 · one of two readings recorded this
Phenotypic index 1 h midazolam/1′-hydroxymidazolam
increases, p = 0.01, n = 17
the phenotypic indices of 1 h midazolam/1′-hydroxymidazolam increased 59% (P<0.01)
PMID:21870106 · one of two readings recorded this
Correlation of berberine-induced LDL-C reduction with reduction from stable therapy
decreases, p = 0.0001
In HeFH patients the addition of BBR resulted in LDL cholesterol reductions inversely related to those induced by the stable therapy (r = -0.617, P <0.0001), with mean 10.5% further decrease
PMID:22998978 · one of two readings recorded this
LDL-C percent change by NPC1L1 g.1679 C>G genotype
decreases, p = 0.001
the subjects carrying the G allele of the g.1679 C > G silent polymorphism of NPC1L1 gene showed a higher response to EZE than homozygous for the common allele (GG + CG: LDL-C -29.4±5.0%, CC -23.6±6.5%, P <0.001)
PMID:22998978 · one of two readings recorded this
LDL cholesterol further decrease
decreases
In HeFH patients the addition of BBR resulted in LDL cholesterol reductions inversely related to those induced by the stable therapy (r = -0.617, P <0.0001), with mean 10.5% further decrease
PMID:22998978 · one of two readings recorded this
LDL cholesterol lowering, percent change, in hypercholesterolemic subjects
-31.7% vs -25.4% (nutraceutical pill vs ezetimibe)
Not recorded as a finding: the comparison was against another active treatment
In HCH subjects the nutraceutical pill resulted more effective than EZE in lowering LDL cholesterol (-31.7% vs -25.4%, P < 0.001) and better tolerated.
PMID:22998978 · one of two readings recorded this
LDL cholesterol percent change
decreases, p = 0.001
In HCH subjects the nutraceutical pill resulted more effective than EZE in lowering LDL cholesterol (-31.7% vs -25.4%, P < 0.001) and better tolerated
PMID:22998978 · one of two readings recorded this
LDL cholesterol percent change
decreases
Combined treatment with these drugs was as effective as STs in moderate doses (LDL cholesterol -37%, triglycerides -23%)
PMID:22998978 · one of two readings recorded this
LDL cholesterol percentage change, nutraceutical pill containing berberine versus ezetimibe
decreases, LDL-C -31.7% vs -25.4% for ezetimibe
Not recorded as a finding: the comparison was against another active treatment
In HCH subjects the nutraceutical pill resulted more effective than EZE in lowering LDL cholesterol (-31.7% vs -25.4%, P < 0.001) and better tolerated.
PMID:22998978 · one of two readings recorded this
Proportion reaching LDL-C below 3.36 mmol/L
increases, p = 0.007
On treatment, LDL-C level below 3.36 mmol/L (≤130 mg/dl) was observed in 28.9% of subjects treated with the nutraceutical pill and 11.8% of those treated with EZE (P <0.007)
PMID:22998978 · one of two readings recorded this
Triglycerides percent change
decreases
Combined treatment with these drugs was as effective as STs in moderate doses (LDL cholesterol -37%, triglycerides -23%)
PMID:22998978 · one of two readings recorded this
HOMA-IR
decreases, p = 0.014
HOMA-IR | -0.26(-0.72~0.20) | -0.69(-1.18~-0.20) | -1.06(-1.51~-0.61) | 0.014 | 0.298
PMID:26252777 · one of two readings recorded this
HOMA-IR
decreases, p = 0.298
HOMA-IR | -0.26(-0.72~0.20) | -0.69(-1.18~-0.20) | -1.06(-1.51~-0.61) | 0.014 | 0.298
PMID:26252777 · one of two readings recorded this
HOMA-IR
no effect
HOMA-IR | -0.26(-0.72~0.20) | -0.69(-1.18~-0.20) | -1.06(-1.51~-0.61) | 0.014 | 0.298
PMID:26252777 · one of two readings recorded this
Triglycerides
decreases, p = 0.007
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
Triglycerides
no effect, p = 0.05
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
Triglycerides
no effect
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
Apolipoprotein E
decreases, p = 0.143
APO-E(mg/L) | -7.0(-10.7~-3.2) | -8.9(-13.0~-4.8) | -10.9(-14.6~-7.2) | 0.143 | 0.476
PMID:26252777 · one of two readings recorded this
Apolipoprotein E
decreases, p = 0.476
APO-E(mg/L) | -7.0(-10.7~-3.2) | -8.9(-13.0~-4.8) | -10.9(-14.6~-7.2) | 0.143 | 0.476
PMID:26252777 · one of two readings recorded this
Apolipoprotein E
decreases
APO-E(mg/L) | -7.0(-10.7~-3.2) | -8.9(-13.0~-4.8) | -10.9(-14.6~-7.2) | 0.143 | 0.476
PMID:26252777 · one of two readings recorded this
AST
decreases, p = 0.05
AST | -6.5(-8.2~-4.8) | -8.3(-10.2~-6.4) | -8.9(-10.7~-7.2) | 0.050 | 0.632
PMID:26252777 · one of two readings recorded this
AST
decreases, p = 0.632
AST | -6.5(-8.2~-4.8) | -8.3(-10.2~-6.4) | -8.9(-10.7~-7.2) | 0.050 | 0.632
PMID:26252777 · one of two readings recorded this
AST
decreases
AST | -6.5(-8.2~-4.8) | -8.3(-10.2~-6.4) | -8.9(-10.7~-7.2) | 0.050 | 0.632
PMID:26252777 · one of two readings recorded this
ALT reduction
no effect, p = 0.855
the reduction of ALT and AST showed no significant difference between the LSI plus BBR and LSI plus PGZ groups at the 16th week (p = 0.855 and p = 0.632, respectively)
PMID:26252777 · one of two readings recorded this
ALT
decreases, p = 0.015
ALT | -14.1(-18.0~-10.2) | -20.5(-24.8~-16.2) | -21.0(-24.9~-17.1) | 0.015 | 0.855
PMID:26252777 · one of two readings recorded this
ALT
decreases, p = 0.855
ALT | -14.1(-18.0~-10.2) | -20.5(-24.8~-16.2) | -21.0(-24.9~-17.1) | 0.015 | 0.855
PMID:26252777 · one of two readings recorded this
ALT
decreases
ALT | -14.1(-18.0~-10.2) | -20.5(-24.8~-16.2) | -21.0(-24.9~-17.1) | 0.015 | 0.855
PMID:26252777 · one of two readings recorded this
Apolipoprotein A
decreases, p = 0.055
APO-A(g/L) | -0.01(-0.07~0.05) | -0.00(-0.06~0.07) | -0.09(-0.15~-0.03) | 0.055 | 0.036
PMID:26252777 · one of two readings recorded this
Apolipoprotein A
no effect, p = 0.036
APO-A(g/L) | -0.01(-0.07~0.05) | -0.00(-0.06~0.07) | -0.09(-0.15~-0.03) | 0.055 | 0.036
PMID:26252777 · one of two readings recorded this
Apolipoprotein A
no effect
APO-A(g/L) | -0.01(-0.07~0.05) | -0.00(-0.06~0.07) | -0.09(-0.15~-0.03) | 0.055 | 0.036
PMID:26252777 · one of two readings recorded this
Apolipoprotein B
decreases, p = 0.022
APO-B(g/L) | -0.05(-0.09~-0.01) | -0.05(-0.09~-0.00) | -0.12(-0.16~-0.08) | 0.022 | 0.023
PMID:26252777 · one of two readings recorded this
Apolipoprotein B
decreases, p = 0.023
APO-B(g/L) | -0.05(-0.09~-0.01) | -0.05(-0.09~-0.00) | -0.12(-0.16~-0.08) | 0.022 | 0.023
PMID:26252777 · one of two readings recorded this
Apolipoprotein B
decreases
APO-B(g/L) | -0.05(-0.09~-0.01) | -0.05(-0.09~-0.00) | -0.12(-0.16~-0.08) | 0.022 | 0.023
PMID:26252777 · one of two readings recorded this
AST reduction
no effect, p = 0.632
the reduction of ALT and AST showed no significant difference between the LSI plus BBR and LSI plus PGZ groups at the 16th week (p = 0.855 and p = 0.632, respectively)
PMID:26252777 · one of two readings recorded this
Blood glucose 0min
decreases, p = 0.096
0min | -0.15(-0.41~-0.12) | -0.38(-0.66~-0.10) | -0.47(-0.73~-0.20) | 0.096 | 0.658
PMID:26252777 · one of two readings recorded this
Blood glucose 0min
decreases, p = 0.658
0min | -0.15(-0.41~-0.12) | -0.38(-0.66~-0.10) | -0.47(-0.73~-0.20) | 0.096 | 0.658
PMID:26252777 · one of two readings recorded this
Blood glucose 0min
decreases
0min | -0.15(-0.41~-0.12) | -0.38(-0.66~-0.10) | -0.47(-0.73~-0.20) | 0.096 | 0.658
PMID:26252777 · one of two readings recorded this
Blood glucose 120min
decreases, p = 0.02
120min | -1.05(-1.73~-0.37) | -2.44(-3.17~-1.72) | -2.19(-2.87~-1.51) | 0.020 | 0.609
PMID:26252777 · one of two readings recorded this
Blood glucose 120min
decreases, p = 0.609
120min | -1.05(-1.73~-0.37) | -2.44(-3.17~-1.72) | -2.19(-2.87~-1.51) | 0.020 | 0.609
PMID:26252777 · one of two readings recorded this
Blood glucose 120min
decreases
120min | -1.05(-1.73~-0.37) | -2.44(-3.17~-1.72) | -2.19(-2.87~-1.51) | 0.020 | 0.609
PMID:26252777 · one of two readings recorded this
Blood glucose 180min
decreases, p = 0.042
180min | -0.90(-1.35~-0.44) | -1.48(-1.97~-1.00) | -1.57(-2.02~-1.11) | 0.042 | 0.799
PMID:26252777 · one of two readings recorded this
Blood glucose 180min
decreases, p = 0.799
180min | -0.90(-1.35~-0.44) | -1.48(-1.97~-1.00) | -1.57(-2.02~-1.11) | 0.042 | 0.799
PMID:26252777 · one of two readings recorded this
Blood glucose 180min
decreases
180min | -0.90(-1.35~-0.44) | -1.48(-1.97~-1.00) | -1.57(-2.02~-1.11) | 0.042 | 0.799
PMID:26252777 · one of two readings recorded this
Blood glucose 30min
decreases, p = 0.196
30min | -0.63(-1.06~-0.19) | -0.91(-1.38~-0.45) | -1.03(-1.46~-0.60) | 0.196 | 0.725
PMID:26252777 · one of two readings recorded this
Blood glucose 30min
decreases, p = 0.725
30min | -0.63(-1.06~-0.19) | -0.91(-1.38~-0.45) | -1.03(-1.46~-0.60) | 0.196 | 0.725
PMID:26252777 · one of two readings recorded this
Blood glucose 30min
decreases
30min | -0.63(-1.06~-0.19) | -0.91(-1.38~-0.45) | -1.03(-1.46~-0.60) | 0.196 | 0.725
PMID:26252777 · one of two readings recorded this
Blood glucose 60min
decreases, p = 0.125
60min | -1.23(-1.80~-0.65) | -1.18(-1.79~-0.57) | -1.86(-2.42~-1.29) | 0.125 | 0.112
PMID:26252777 · one of two readings recorded this
Blood glucose 60min
decreases, p = 0.112
60min | -1.23(-1.80~-0.65) | -1.18(-1.79~-0.57) | -1.86(-2.42~-1.29) | 0.125 | 0.112
PMID:26252777 · one of two readings recorded this
Blood glucose 60min
decreases
60min | -1.23(-1.80~-0.65) | -1.18(-1.79~-0.57) | -1.86(-2.42~-1.29) | 0.125 | 0.112
PMID:26252777 · one of two readings recorded this
BMI
decreases, p = 0.001
BMI(kg/m2) | -0.72(-0.99~-0.44) | -0.67(-0.97~-0.38) | -1.51(-1.79~-1.25) | <0.001 | <0.001
PMID:26252777 · one of two readings recorded this
BMI
decreases, p = 0.001
BMI(kg/m2) | -0.72(-0.99~-0.44) | -0.67(-0.97~-0.38) | -1.51(-1.79~-1.25) | <0.001 | <0.001
PMID:26252777 · one of two readings recorded this
BMI
decreases
BMI(kg/m2) | -0.72(-0.99~-0.44) | -0.67(-0.97~-0.38) | -1.51(-1.79~-1.25) | <0.001 | <0.001
PMID:26252777 · one of two readings recorded this
Glucose AUC (AUCg)
decreases, p = 0.015
AUCg | -3.33(-4.93~-1.73) | -5.51(-7.21~-3.81) | -6.14(-7.72~-4.55) | 0.015 | 0.594
PMID:26252777 · one of two readings recorded this
Glucose AUC (AUCg)
decreases, p = 0.594
AUCg | -3.33(-4.93~-1.73) | -5.51(-7.21~-3.81) | -6.14(-7.72~-4.55) | 0.015 | 0.594
PMID:26252777 · one of two readings recorded this
Glucose AUC (AUCg)
decreases
AUCg | -3.33(-4.93~-1.73) | -5.51(-7.21~-3.81) | -6.14(-7.72~-4.55) | 0.015 | 0.594
PMID:26252777 · one of two readings recorded this
γ-GT
decreases, p = 0.403
γ-GT | -8.4(-13.9~-3.0) | -14.3(-20.2~-8.5) | -11.7(-17.1~-6.3) | 0.403 | 0.517
PMID:26252777 · one of two readings recorded this
γ-GT
decreases, p = 0.517
γ-GT | -8.4(-13.9~-3.0) | -14.3(-20.2~-8.5) | -11.7(-17.1~-6.3) | 0.403 | 0.517
PMID:26252777 · one of two readings recorded this
γ-GT
decreases
γ-GT | -8.4(-13.9~-3.0) | -14.3(-20.2~-8.5) | -11.7(-17.1~-6.3) | 0.403 | 0.517
PMID:26252777 · one of two readings recorded this
HbA1c
decreases, p = 0.078
HbA1c(%) | -0.30(-0.43~-0.16) | -0.44(-0.58~-0.30) | -0.47(-0.60~-0.33) | 0.078 | 0.793
PMID:26252777 · one of two readings recorded this
HbA1c
decreases, p = 0.793
HbA1c(%) | -0.30(-0.43~-0.16) | -0.44(-0.58~-0.30) | -0.47(-0.60~-0.33) | 0.078 | 0.793
PMID:26252777 · one of two readings recorded this
HbA1c
decreases
HbA1c(%) | -0.30(-0.43~-0.16) | -0.44(-0.58~-0.30) | -0.47(-0.60~-0.33) | 0.078 | 0.793
PMID:26252777 · one of two readings recorded this
HDL-c
no effect, p = 0.861
HDL-c(mmol/L) | 0.005(-0.034~0.044) | 0.065(0.023~0.107) | 0.010(-0.029~0.049) | 0.861 | 0.061
PMID:26252777 · one of two readings recorded this
HDL-c
increases, p = 0.061
HDL-c(mmol/L) | 0.005(-0.034~0.044) | 0.065(0.023~0.107) | 0.010(-0.029~0.049) | 0.861 | 0.061
PMID:26252777 · one of two readings recorded this
HDL-c
no effect
HDL-c(mmol/L) | 0.005(-0.034~0.044) | 0.065(0.023~0.107) | 0.010(-0.029~0.049) | 0.861 | 0.061
PMID:26252777 · one of two readings recorded this
hepatic fat content by 1H MRS, percent (primary endpoint)
decreases, berberine plus lifestyle versus lifestyle alone, p = 0.008, p = 0.008
Not recorded as a finding: No hepatic fat content outcome node in the list
Treatment with LSI plus BBR caused more reduction of HFC as compared to that with LSI alone (p = 0.008, Fig 2).
PMID:26252777 · one of two readings recorded this
hepatic fat content (HFC, %) by 1H magnetic resonance spectroscopy, primary outcome
decreases, LSI plus BBR more reduction than LSI alone, p = 0.008, p = 0.008
Not recorded as a finding: No outcome node for hepatic fat content by 1H MRS.
Treatment with LSI plus BBR caused more reduction of HFC as compared to that with LSI alone (p = 0.008, Fig 2).
PMID:26252777 · one of two readings recorded this
HFC percent decrease
no effect, p = 0.054
Moreover, the effect of BBR on HFC was no smaller than that of PGZ (15mg per day) (p = 0.054)
PMID:26252777 · one of two readings recorded this
HFC percent decrease
decreases, p = 0.008
Treatment with LSI plus BBR caused more reduction of HFC as compared to that with LSI alone (p = 0.008, Fig 2)
PMID:26252777 · one of two readings recorded this
HFC percent decrease
decreases, p = 0.001
After treatment, HFC decreased by 57.2% in the LSI plus BBR group (P<0.001) and by 36.4% in the LSI group (P<0.001)
PMID:26252777 · one of two readings recorded this
HFC percent decrease
decreases, p = 0.001
After treatment, HFC decreased by 57.2% in the LSI plus BBR group (P<0.001) and by 36.4% in the LSI group (P<0.001)
PMID:26252777 · one of two readings recorded this
HFC
decreases, p = 0.008
HFC(%) | -11.4(-14.8~-7.9) | -12.1(-15.8~-8.5) | -17.4(-20.8~-14.0) | 0.008 | 0.054
PMID:26252777 · one of two readings recorded this
HFC
decreases, p = 0.054
HFC(%) | -11.4(-14.8~-7.9) | -12.1(-15.8~-8.5) | -17.4(-20.8~-14.0) | 0.008 | 0.054
PMID:26252777 · one of two readings recorded this
HFC
decreases
HFC(%) | -11.4(-14.8~-7.9) | -12.1(-15.8~-8.5) | -17.4(-20.8~-14.0) | 0.008 | 0.054
PMID:26252777 · one of two readings recorded this
LDL-c
decreases, p = 0.442
LDL-c(mmol/L) | -0.14(-0.32~0.04) | -0.05(-0.25~0.14) | -0.24(-0.42~-0.07) | 0.442 | 0.154
PMID:26252777 · one of two readings recorded this
LDL-c
no effect, p = 0.154
LDL-c(mmol/L) | -0.14(-0.32~0.04) | -0.05(-0.25~0.14) | -0.24(-0.42~-0.07) | 0.442 | 0.154
PMID:26252777 · one of two readings recorded this
LDL-c
no effect
LDL-c(mmol/L) | -0.14(-0.32~0.04) | -0.05(-0.25~0.14) | -0.24(-0.42~-0.07) | 0.442 | 0.154
PMID:26252777 · one of two readings recorded this
Lipoprotein(a)
no effect, p = 0.319
LP(a)(mg/L) | 4.53(-22.3~31.3) | 17.8(-11.2~46.9) | 23.6(-2.9~50.1) | 0.319 | 0.774
PMID:26252777 · one of two readings recorded this
Lipoprotein(a)
no effect, p = 0.774
LP(a)(mg/L) | 4.53(-22.3~31.3) | 17.8(-11.2~46.9) | 23.6(-2.9~50.1) | 0.319 | 0.774
PMID:26252777 · one of two readings recorded this
Lipoprotein(a)
no effect
LP(a)(mg/L) | 4.53(-22.3~31.3) | 17.8(-11.2~46.9) | 23.6(-2.9~50.1) | 0.319 | 0.774
PMID:26252777 · one of two readings recorded this
Rat body weight after single-dose BBR
no effect, p = 0.103
Body weight (g) | 428.50±20.79 | 391.00±20.15 | 400.00±39.59 | 426.67±21.96 | 429.00±35.38 | 402.50±31.50 | 0.103
PMID:26252777 · one of two readings recorded this
Rat serum ALT after single-dose BBR
decreases, p = 0.002
ALT | 92.67±52.79 | 47.17±5.91 | 39.33±7.23 | 46.17±6.59 | 79.17±18.71 | 75.67±17.0 | 0.002
PMID:26252777 · one of two readings recorded this
Rat serum AST after single-dose BBR
decreases, p = 0.001
AST | 376.67±197.57 | 143.83±13.18 | 126.17±24.26 | 139.17±24.98 | 270.33±41.00 | 297.83±89.60 | <0.001
PMID:26252777 · one of two readings recorded this
Rat serum triglycerides after single-dose BBR
increases, p = 0.001
TG | 0.36±0.08 | 0.70±0.23 | 0.49±0.19 | 0.34±0.09 | 0.70±0.28 | 0.83±0.17 | <0.001
PMID:26252777 · one of two readings recorded this
Serum insulin 0min
decreases, p = 0.515
0min | -0.85(-2.43~0.72) | -1.66(-3.35~0.02) | -1.59(-3.14~-0.03) | 0.515 | 0.949
PMID:26252777 · one of two readings recorded this
Serum insulin 0min
no effect, p = 0.949
0min | -0.85(-2.43~0.72) | -1.66(-3.35~0.02) | -1.59(-3.14~-0.03) | 0.515 | 0.949
PMID:26252777 · one of two readings recorded this
Serum insulin 0min
no effect
0min | -0.85(-2.43~0.72) | -1.66(-3.35~0.02) | -1.59(-3.14~-0.03) | 0.515 | 0.949
PMID:26252777 · one of two readings recorded this
Serum insulin 120min
no effect, p = 0.102
120min | 4.5(-10.9~19.9) | -15.4(-32.0~1.1) | -13.6(-28.9~1.7) | 0.102 | 0.874
PMID:26252777 · one of two readings recorded this
Serum insulin 120min
no effect, p = 0.874
120min | 4.5(-10.9~19.9) | -15.4(-32.0~1.1) | -13.6(-28.9~1.7) | 0.102 | 0.874
PMID:26252777 · one of two readings recorded this
Serum insulin 120min
no effect
120min | 4.5(-10.9~19.9) | -15.4(-32.0~1.1) | -13.6(-28.9~1.7) | 0.102 | 0.874
PMID:26252777 · one of two readings recorded this
Serum insulin 30min
no effect, p = 0.098
30min | -3.10(-11.54~5.35) | 1.24(-7.73~10.22) | 6.93(-1.35~15.20) | 0.098 | 0.362
PMID:26252777 · one of two readings recorded this
Serum insulin 30min
no effect, p = 0.362
30min | -3.10(-11.54~5.35) | 1.24(-7.73~10.22) | 6.93(-1.35~15.20) | 0.098 | 0.362
PMID:26252777 · one of two readings recorded this
Serum insulin 30min
no effect
30min | -3.10(-11.54~5.35) | 1.24(-7.73~10.22) | 6.93(-1.35~15.20) | 0.098 | 0.362
PMID:26252777 · one of two readings recorded this
Total cholesterol
decreases, p = 0.004
TC(mmol/L) | -0.12(-0.31~0.07) | -0.11(-0.31~0.10) | -0.52(-0.71~-0.33) | 0.004 | 0.004
PMID:26252777 · one of two readings recorded this
Total cholesterol
no effect, p = 0.004
TC(mmol/L) | -0.12(-0.31~0.07) | -0.11(-0.31~0.10) | -0.52(-0.71~-0.33) | 0.004 | 0.004
PMID:26252777 · one of two readings recorded this
Total cholesterol
no effect
TC(mmol/L) | -0.12(-0.31~0.07) | -0.11(-0.31~0.10) | -0.52(-0.71~-0.33) | 0.004 | 0.004
PMID:26252777 · one of two readings recorded this
Waist circumference
decreases, p = 0.001
Waist (cm) | -2.14(-3.03~-1.26) | -2.60(-3.55~-1.66) | -4.84(-5.70~-3.97) | <0.001 | 0.001
PMID:26252777 · one of two readings recorded this
Waist circumference
decreases, p = 0.001
Waist (cm) | -2.14(-3.03~-1.26) | -2.60(-3.55~-1.66) | -4.84(-5.70~-3.97) | <0.001 | 0.001
PMID:26252777 · one of two readings recorded this
Waist circumference
decreases
Waist (cm) | -2.14(-3.03~-1.26) | -2.60(-3.55~-1.66) | -4.84(-5.70~-3.97) | <0.001 | 0.001
PMID:26252777 · one of two readings recorded this
Weight
decreases, p = 0.001
Weight (kg) | -1.99(-2.76~-1.23) | -1.94(-2.75~-1.12) | -4.29(-5.04~-3.54) | <0.001 | <0.001
PMID:26252777 · one of two readings recorded this
Weight
decreases, p = 0.001
Weight (kg) | -1.99(-2.76~-1.23) | -1.94(-2.75~-1.12) | -4.29(-5.04~-3.54) | <0.001 | <0.001
PMID:26252777 · one of two readings recorded this
Weight
decreases
Weight (kg) | -1.99(-2.76~-1.23) | -1.94(-2.75~-1.12) | -4.29(-5.04~-3.54) | <0.001 | <0.001
PMID:26252777 · one of two readings recorded this
LDL cholesterol
decreases
Sex hormone binding globulin, insulin resistance, total cholesterol, total triglyceride and low-density lipoprotein cholesterol decreased after berberine treatment in the normal weight group only
PMID:26645811 · one of two readings recorded this
Completion of four month treatment
unclear, n = 102
A total of 98 of 102 subjects (96.1%) completed the four month treatment
PMID:26645811 · one of two readings recorded this
Insulin resistance
decreases
Sex hormone binding globulin, insulin resistance, total cholesterol, total triglyceride and low-density lipoprotein cholesterol decreased after berberine treatment in the normal weight group only
PMID:26645811 · one of two readings recorded this
ovulation rate confirmed by serum progesterone >=10 ng/ml, menstrual pattern, SHBG, insulin resistance, lipids in anovulatory women with PCOS
ovulation rate 25.0% over four months in the whole group
Not recorded as a finding: the result compares a group with itself, not with a control
The ovulation rate was 25.0% over four months in the whole group, 22.5% in the normal weight group and 31.0% in the overweight/obese group.
PMID:26645811 · one of two readings recorded this
Ovulation rate over four months
increases
The ovulation rate was 25.0% over four months in the whole group, 22.5% in the normal weight group and 31.0% in the overweight/obese group
PMID:26645811 · one of two readings recorded this
Ovulation rate over four months
increases
The ovulation rate was 25.0% over four months in the whole group, 22.5% in the normal weight group and 31.0% in the overweight/obese group
PMID:26645811 · one of two readings recorded this
Ovulation rate over four months
increases
The ovulation rate was 25.0% over four months in the whole group, 22.5% in the normal weight group and 31.0% in the overweight/obese group
PMID:26645811 · one of two readings recorded this
Regained regular menses, normal weight vs overweight/obese
no effect
Fourteen women (14.3%, 14/98) had regained regular menses after berberine treatment and there was no significant difference between normal weight and overweight/obese groups
PMID:26645811 · one of two readings recorded this
Regained regular menses
increases, n = 98
Fourteen women (14.3%, 14/98) had regained regular menses after berberine treatment and there was no significant difference between normal weight and overweight/obese groups
PMID:26645811 · one of two readings recorded this
Sex hormone binding globulin
decreases
Sex hormone binding globulin, insulin resistance, total cholesterol, total triglyceride and low-density lipoprotein cholesterol decreased after berberine treatment in the normal weight group only
PMID:26645811 · one of two readings recorded this
Total cholesterol
decreases
Sex hormone binding globulin, insulin resistance, total cholesterol, total triglyceride and low-density lipoprotein cholesterol decreased after berberine treatment in the normal weight group only
PMID:26645811 · one of two readings recorded this
Total triglyceride
decreases
Sex hormone binding globulin, insulin resistance, total cholesterol, total triglyceride and low-density lipoprotein cholesterol decreased after berberine treatment in the normal weight group only
PMID:26645811 · one of two readings recorded this
HOMA-IR
no effect, p = 0.21
HOMA-IR | 3.6 (2.4–4.1) | 2.8 (2.2–3.9) | 0.21 | 3.7 (2.5–5.0) | 3.4 (1.8–5.1) | 0.32
PMID:27629750 · one of two readings recorded this
HOMA-IR
no effect, p = 0.32
HOMA-IR | 3.6 (2.4–4.1) | 2.8 (2.2–3.9) | 0.21 | 3.7 (2.5–5.0) | 3.4 (1.8–5.1) | 0.32
PMID:27629750 · one of two readings recorded this
Triglycerides
decreases, p = 0.05
TG (mmol/L) | 2.2 ± 1.2 | 1.6 ± 0.9 | P < 0.05 | 2.0 ± 0.8 | 1.9 ± 1.1 | 0.69
PMID:27629750 · one of two readings recorded this
Triglycerides
no effect, p = 0.69
TG (mmol/L) | 2.2 ± 1.2 | 1.6 ± 0.9 | P < 0.05 | 2.0 ± 0.8 | 1.9 ± 1.1 | 0.69
PMID:27629750 · one of two readings recorded this
Apolipoprotein E
no effect, p = 0.08
APO-E (mg/L) | 48.0 (37.0–57.3) | 42.5 (36.0–49.7) | 0.08 | 44.0 (37.9–52.3) | 44.0 (38.5–56.5) | 0.94
PMID:27629750 · one of two readings recorded this
Apolipoprotein E
no effect, p = 0.94
APO-E (mg/L) | 48.0 (37.0–57.3) | 42.5 (36.0–49.7) | 0.08 | 44.0 (37.9–52.3) | 44.0 (38.5–56.5) | 0.94
PMID:27629750 · one of two readings recorded this
AST
decreases, p = 0.01
AST | 25.0 (20.0–32.0) | 19.0 (16.0–22.5) | P < 0.01 | 25.0 (20.0–30.0) | 20.5 (15.8–27.0) | P < 0.05
PMID:27629750 · one of two readings recorded this
AST
decreases, p = 0.05
AST | 25.0 (20.0–32.0) | 19.0 (16.0–22.5) | P < 0.01 | 25.0 (20.0–30.0) | 20.5 (15.8–27.0) | P < 0.05
PMID:27629750 · one of two readings recorded this
ALT
decreases, p = 0.01
ALT | 36.0 (24.5–47.0) | 21.0 (13.5–29.5) | P < 0.01 | 34.0 (25.3–46.5) | 21.0 (15.0–36.3) | P < 0.01
PMID:27629750 · one of two readings recorded this
ALT
decreases, p = 0.01
ALT | 36.0 (24.5–47.0) | 21.0 (13.5–29.5) | P < 0.01 | 34.0 (25.3–46.5) | 21.0 (15.0–36.3) | P < 0.01
PMID:27629750 · one of two readings recorded this
Apolipoprotein A
decreases, p = 0.05
APO-A(g/L) | 1.3 (1.1–1.4) | 1.2 (1.0–1.3) | P < 0.05 | 1.3 (1.0–1.4) | 1.3 (1.1–1.5) | 0.89
PMID:27629750 · one of two readings recorded this
Apolipoprotein A
no effect, p = 0.89
APO-A(g/L) | 1.3 (1.1–1.4) | 1.2 (1.0–1.3) | P < 0.05 | 1.3 (1.0–1.4) | 1.3 (1.1–1.5) | 0.89
PMID:27629750 · one of two readings recorded this
Apolipoprotein B
decreases, p = 0.05
APO-B(g/L) | 1.0 ± 0.2 | 0.9 ± 0.2 | P < 0.05 | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.28
PMID:27629750 · one of two readings recorded this
Apolipoprotein B
no effect, p = 0.28
APO-B(g/L) | 1.0 ± 0.2 | 0.9 ± 0.2 | P < 0.05 | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.28
PMID:27629750 · one of two readings recorded this
area under the 0-3 h OGTT glucose curve (AUCg)
decreases, -5.9 (-6.9 to -4.8) vs -4.0 (-4.6 to -1.9), P = 0.041, p = 0.041
Not recorded as a finding: Near-miss for postprandial-glucose-auc, which requires an incremental AUC over 60-120 min after a fixed drink or load; this is a 180-minute total-glucose OGTT area.
BBR reduced the area under the OGTT curve [−5.9(−6.9 to −4.8) vs. −4.0(−4.6 to −1.9), P = 0.041] more than lifestyle intervention alone.
PMID:27629750 · one of two readings recorded this
Area under the OGTT curve change
decreases, p = 0.041
BBR reduced the area under the OGTT curve [−5.9(−6.9 to −4.8) vs. −4.0(−4.6 to −1.9), P = 0.041] more than lifestyle intervention alone
PMID:27629750 · one of two readings recorded this
Blood glucose 0 min
decreases, p = 0.01
0 min | 6.4 ± 0.9 | 6.1 ± 1.3 | <0.01 | 6.2 ± 1.0 | 6.2 ± 0.9 | 0.47
PMID:27629750 · one of two readings recorded this
Blood glucose 0 min
no effect, p = 0.47
0 min | 6.4 ± 0.9 | 6.1 ± 1.3 | <0.01 | 6.2 ± 1.0 | 6.2 ± 0.9 | 0.47
PMID:27629750 · one of two readings recorded this
Blood glucose 120 min
decreases, p = 0.05
120 min | 11.2 ± 3.0 | 8.6 ± 2.8 | <0.05 | 10.8 ± 3.3 | 10.1 ± 2.9 | 0.14
PMID:27629750 · one of two readings recorded this
Blood glucose 120 min
no effect, p = 0.14
120 min | 11.2 ± 3.0 | 8.6 ± 2.8 | <0.05 | 10.8 ± 3.3 | 10.1 ± 2.9 | 0.14
PMID:27629750 · one of two readings recorded this
Blood glucose 180 min
decreases, p = 0.05
180 min | 7.2 ± 2.3 | 5.4 ± 1.6 | <0.05 | 6.5 ± 2.8 | 5.9 ± 2.3 | <0.05
PMID:27629750 · one of two readings recorded this
Blood glucose 180 min
decreases, p = 0.05
180 min | 7.2 ± 2.3 | 5.4 ± 1.6 | <0.05 | 6.5 ± 2.8 | 5.9 ± 2.3 | <0.05
PMID:27629750 · one of two readings recorded this
Blood glucose 30 min
decreases, p = 0.05
30 min | 11.1 ± 1.7 | 9.9 ± 1.9 | <0.05 | 11.0 ± 1.7 | 10.4 ± 2.1 | 0.13
PMID:27629750 · one of two readings recorded this
Blood glucose 30 min
no effect, p = 0.13
30 min | 11.1 ± 1.7 | 9.9 ± 1.9 | <0.05 | 11.0 ± 1.7 | 10.4 ± 2.1 | 0.13
PMID:27629750 · one of two readings recorded this
Blood glucose 60 min
decreases, p = 0.05
60 min | 13.1 ± 2.5 | 11.1 ± 2.6 | <0.05 | 13.0 ± 2.6 | 11.9 ± 3.1 | <0.05
PMID:27629750 · one of two readings recorded this
Blood glucose 60 min
decreases, p = 0.05
60 min | 13.1 ± 2.5 | 11.1 ± 2.6 | <0.05 | 13.0 ± 2.6 | 11.9 ± 3.1 | <0.05
PMID:27629750 · one of two readings recorded this
BMI
decreases, p = 0.01
BMI (kg/m2) | 27.4 ± 4.1 | 25.5 ± 3.3 | <0.01 | 27.3 ± 3.0 | 26.0 ± 5.9 | <0.05
PMID:27629750 · one of two readings recorded this
BMI
decreases, p = 0.05
BMI (kg/m2) | 27.4 ± 4.1 | 25.5 ± 3.3 | <0.01 | 27.3 ± 3.0 | 26.0 ± 5.9 | <0.05
PMID:27629750 · one of two readings recorded this
glucose area under the curve over a 3-hour OGTT
decreases, -5.9 (-6.9 to -4.8) vs -4.0 (-4.6 to -1.9), P = 0.041, p = 0.041
Not recorded as a finding: postprandial-glucose-auc requires an incremental AUC over 60 to 120 minutes after a fixed load; this is a 0 to 180 min OGTT curve area, so a near miss
BBR reduced the area under the OGTT curve [−5.9(−6.9 to −4.8) vs. −4.0(−4.6 to −1.9), P = 0.041] more than lifestyle intervention alone.
PMID:27629750 · one of two readings recorded this
Glucose AUC (AUCg)
decreases, p = 0.05
AUCg | 42.4 ± 7.6 | 36.3 ± 8.4 | <0.05 | 41.2 ± 8.4 | 39.1 ± 9.3 | <0.05
PMID:27629750 · one of two readings recorded this
Glucose AUC (AUCg)
decreases, p = 0.05
AUCg | 42.4 ± 7.6 | 36.3 ± 8.4 | <0.05 | 41.2 ± 8.4 | 39.1 ± 9.3 | <0.05
PMID:27629750 · one of two readings recorded this
γ-GT
decreases, p = 0.01
γ-GT | 39.0 (26.0–67.5) | 30.0 (23.0–43.0) | P < 0.01 | 33.0 (22.0–56.5) | 27.5 (20.5–48.8) | P < 0.05
PMID:27629750 · one of two readings recorded this
γ-GT
decreases, p = 0.05
γ-GT | 39.0 (26.0–67.5) | 30.0 (23.0–43.0) | P < 0.01 | 33.0 (22.0–56.5) | 27.5 (20.5–48.8) | P < 0.05
PMID:27629750 · one of two readings recorded this
HbA1c
decreases, p = 0.01
HbA1c (%) | 6.4 ± 0.7 | 6.0 ± 0.4 | <0.01 | 6.3 ± 0.7 | 6.2 ± 0.7 | 0.11
PMID:27629750 · one of two readings recorded this
HbA1c
no effect, p = 0.11
HbA1c (%) | 6.4 ± 0.7 | 6.0 ± 0.4 | <0.01 | 6.3 ± 0.7 | 6.2 ± 0.7 | 0.11
PMID:27629750 · one of two readings recorded this
HDL-c
no effect, p = 0.65
HDL-c (mmol/L) | 1.2 ± 0.2 | 1.2 ± 0.3 | 0.65 | 1.2 ± 0.3 | 1.2 ± 0.2 | 0.55
PMID:27629750 · one of two readings recorded this
HDL-c
no effect, p = 0.55
HDL-c (mmol/L) | 1.2 ± 0.2 | 1.2 ± 0.3 | 0.65 | 1.2 ± 0.3 | 1.2 ± 0.2 | 0.55
PMID:27629750 · one of two readings recorded this
hepatic fat content by proton magnetic resonance spectroscopy (1H MRS), percent
decreases, p = 0.021
Not recorded as a finding: No hepatic fat content outcome node in the list
BBR caused a greater reduction in HFC as compared to that with LSI alone (P = 0.021; Additional file 1: Table S1).
PMID:27629750 · one of two readings recorded this
Hepatic fat content decrease
decreases, p = 0.021
BBR caused a greater reduction in HFC as compared to that with LSI alone (P = 0.021; Additional file 1: Table S1)
PMID:27629750 · one of two readings recorded this
Hepatic fat content decrease
decreases
After 16 w treatment, HFC decreased by 55.1 % in the BBR group (P = 0.00) and by 29.3 % in the LSI group (P < 0.05; Table 1)
PMID:27629750 · one of two readings recorded this
Hepatic fat content decrease
decreases, p = 0.05
After 16 w treatment, HFC decreased by 55.1 % in the BBR group (P = 0.00) and by 29.3 % in the LSI group (P < 0.05; Table 1)
PMID:27629750 · one of two readings recorded this
hepatic fat content (HFC, %) by proton magnetic resonance spectroscopy
decreases, BBR greater reduction than LSI alone, P = 0.021, p = 0.021
Not recorded as a finding: No outcome node for hepatic fat content by 1H MRS.
BBR caused a greater reduction in HFC as compared to that with LSI alone (P = 0.021; Additional file 1: Table S1).
PMID:27629750 · one of two readings recorded this
Hepatic fat content (HFC)
decreases, p = 0.01
HFC (%) | 30.3 (22.2–44.0) | 13.6 (9.3–17.4) | <0.01 | 28.7 (21.9–46.8) | 20.3 (11.3–33.0) | <0.05
PMID:27629750 · one of two readings recorded this
Hepatic fat content (HFC)
decreases, p = 0.05
HFC (%) | 30.3 (22.2–44.0) | 13.6 (9.3–17.4) | <0.01 | 28.7 (21.9–46.8) | 20.3 (11.3–33.0) | <0.05
PMID:27629750 · one of two readings recorded this
HOMA-beta
no effect, p = 0.12
HOMAβ | 88.2 (54.3–114.4) | 93.1 (64.1–129.6) | 0.12 | 97.7 (62.2–151.1) | 100.0 (56.8–152.6) | 0.69
PMID:27629750 · one of two readings recorded this
HOMA-beta
no effect, p = 0.69
HOMAβ | 88.2 (54.3–114.4) | 93.1 (64.1–129.6) | 0.12 | 97.7 (62.2–151.1) | 100.0 (56.8–152.6) | 0.69
PMID:27629750 · one of two readings recorded this
ΔI30/ΔG30
increases, p = 0.05
ΔI30/ΔG30 | 8.0 (4.1–13.6) | 10.7 (5.3–20.3) | P < 0.05 | 9.4 (5.0–16.6) | 9.3 (3.6–18.6) | 0.65
PMID:27629750 · one of two readings recorded this
ΔI30/ΔG30
no effect, p = 0.65
ΔI30/ΔG30 | 8.0 (4.1–13.6) | 10.7 (5.3–20.3) | P < 0.05 | 9.4 (5.0–16.6) | 9.3 (3.6–18.6) | 0.65
PMID:27629750 · one of two readings recorded this
LDL-c
decreases, p = 0.05
LDL-c (mmol/L) | 3.2 ± 0.9 | 3.0 ± 0.9 | P < 0.05 | 3.0 ± 0.8 | 3.0 ± 0.8 | 0.73
PMID:27629750 · one of two readings recorded this
LDL-c
no effect, p = 0.73
LDL-c (mmol/L) | 3.2 ± 0.9 | 3.0 ± 0.9 | P < 0.05 | 3.0 ± 0.8 | 3.0 ± 0.8 | 0.73
PMID:27629750 · one of two readings recorded this
Lipoprotein(a)
decreases, p = 0.05
LP(a) (mg/L) | 104.0 (50.0–248.0) | 101.0 (49.5–272.0) | P < 0.05 | 155.0 (78.0–218.0) | 160.0 (90.3–263.0) | 0.23
PMID:27629750 · one of two readings recorded this
Lipoprotein(a)
no effect, p = 0.23
LP(a) (mg/L) | 104.0 (50.0–248.0) | 101.0 (49.5–272.0) | P < 0.05 | 155.0 (78.0–218.0) | 160.0 (90.3–263.0) | 0.23
PMID:27629750 · one of two readings recorded this
Serum Cer(d18:1/18:0)-1-p
decreases, p = 0.033
Cer(d18:1/18:0)-1-p | 472.4 (337.2–668.4) | 423.6 (327.1–497.6) | 0.033 | 491.5 (360.7–635.4) | 459.8 (328.5–542.1) | 0.734
PMID:27629750 · one of two readings recorded this
Serum Cer(d18:1/18:0)-1-p
no effect, p = 0.734
Cer(d18:1/18:0)-1-p | 472.4 (337.2–668.4) | 423.6 (327.1–497.6) | 0.033 | 491.5 (360.7–635.4) | 459.8 (328.5–542.1) | 0.734
PMID:27629750 · one of two readings recorded this
Serum Cer(d18:1/18:0)
decreases, p = 0.033
Cer(d18:1/18:0) | 41.1 (30.4–52.0) | 31.8 (25.1–43.6) | 0.033 | 37.7 (33.3–50.6) | 34.8 (27.1–47.5) | 0.576
PMID:27629750 · one of two readings recorded this
Serum Cer(d18:1/18:0)
no effect, p = 0.576
Cer(d18:1/18:0) | 41.1 (30.4–52.0) | 31.8 (25.1–43.6) | 0.033 | 37.7 (33.3–50.6) | 34.8 (27.1–47.5) | 0.576
PMID:27629750 · one of two readings recorded this
Serum Cer(d18:1/20:0)
decreases, p = 0.047
Cer(d18:1/20:0) | 103.7 (67.0–121.5) | 87.1 (67.3–103.1) | 0.047 | 87.1 (80.9–109.3) | 85.5 (72.9–104.0) | 0.398
PMID:27629750 · one of two readings recorded this
Serum Cer(d18:1/20:0)
no effect, p = 0.398
Cer(d18:1/20:0) | 103.7 (67.0–121.5) | 87.1 (67.3–103.1) | 0.047 | 87.1 (80.9–109.3) | 85.5 (72.9–104.0) | 0.398
PMID:27629750 · one of two readings recorded this
serum cholesterol (not specified as total cholesterol), change versus lifestyle alone
decreases, greater decrease than LSI alone, no figure in sentence
Not recorded as a finding: Sentence says only 'serum cholesterol'; not mapped to the total-cholesterol node to avoid a near-miss. It shares the quoted sentence above.
BBR exhibited greater decreases in body weight, BMI, waist, HFC, serum cholesterol and triglycerides compared with LSI alone (Additional file 1: Table S1), which demonstrates a clearly significant benefit of BBR on metabolism.
PMID:27629750 · one of two readings recorded this
Serum insulin 0 min
no effect, p = 0.97
0 min | 13.4 (8.5–16.2) | 10.8 (8.5–14.1) | 0.97 | 3.4 (8.6–18.6) | 12.4 (7.1–19.1) | 0.89
PMID:27629750 · one of two readings recorded this
Serum insulin 0 min
no effect, p = 0.89
0 min | 13.4 (8.5–16.2) | 10.8 (8.5–14.1) | 0.97 | 3.4 (8.6–18.6) | 12.4 (7.1–19.1) | 0.89
PMID:27629750 · one of two readings recorded this
Serum insulin 120 min
no effect, p = 0.75
120 min | 69.9 (47.5–100.9) | 68.0 (41.2–103.1) | 0.75 | 78.1 (57.1–132.7) | 74.6 (45.7–117.9) | 0.23
PMID:27629750 · one of two readings recorded this
Serum insulin 120 min
no effect, p = 0.23
120 min | 69.9 (47.5–100.9) | 68.0 (41.2–103.1) | 0.75 | 78.1 (57.1–132.7) | 74.6 (45.7–117.9) | 0.23
PMID:27629750 · one of two readings recorded this
Serum insulin 30 min
no effect, p = 0.34
30 min | 41.0 (30.6–62.2) | 47.9 (33.3–88.5) | 0.34 | 59.9 (33.2–83.4) | 54.2 (28.8–77.7) | 0.28
PMID:27629750 · one of two readings recorded this
Serum insulin 30 min
no effect, p = 0.28
30 min | 41.0 (30.6–62.2) | 47.9 (33.3–88.5) | 0.34 | 59.9 (33.2–83.4) | 54.2 (28.8–77.7) | 0.28
PMID:27629750 · one of two readings recorded this
Serum SM(d18:1/16:1)
decreases, p = 0.019
SM(d18:1/16:1) | 266084.4 (183,325.4–335932.6) | 213,504.2 (151,956.4–266,787.1) | 0.019 | 247,807.9 (168,113.3–334,244.5) | 225,052.0 (160,531.6–291,093.4) | 0.247
PMID:27629750 · one of two readings recorded this
Serum SM(d18:1/16:1)
no effect, p = 0.247
SM(d18:1/16:1) | 266084.4 (183,325.4–335932.6) | 213,504.2 (151,956.4–266,787.1) | 0.019 | 247,807.9 (168,113.3–334,244.5) | 225,052.0 (160,531.6–291,093.4) | 0.247
PMID:27629750 · one of two readings recorded this
Sources cited
30 papers
- Subject
- berberine
- Findings
- 56
- Papers
- 30
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.record2026PMID:410870292 findings
The effect of berberine on obesity indices: a systematic review and meta-analysis.record2026PMID:413102572 findings
Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial.record2025PMID:407958461 finding
Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials.record2024PMID:392366622 findings
Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration.record2024PMID:385702761 finding
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.record2024PMID:390423901 finding
Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis.record2024PMID:392410131 finding
Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents.record2023PMID:369033911 finding
Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2023PMID:375987533 findings
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.record2022PMID:350371161 finding
Preventive Effect of Berberine on Postoperative Atrial Fibrillation.record2022PMID:361787422 findings
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.record2022PMID:3631309614 findings
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.record2021PMID:345566701 finding
Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.record2021PMID:344213581 finding
Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial.record2021PMID:344447111 finding
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.record2021PMID:349614183 findings
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.record2021PMID:338122182 findings
The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.record2021PMID:349564361 finding
Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.record2020PMID:318331071 finding
Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes.record2020PMID:323571871 finding
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).record2020PMID:330241201 finding
The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.record2020PMID:326901762 findings
Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2β/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 β-cells.record2019PMID:313379821 finding
Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.record2019PMID:315192921 finding
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.record2018PMID:304669861 finding
Hypoglycemic Mechanism of the Berberine Organic Acid Salt under the Synergistic Effect of Intestinal Flora and Oxidative Stress.record2018PMID:306625841 finding
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.record2017PMID:282418171 finding
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.record2016PMID:276297503 findings
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.record2015PMID:262527771 finding
Repeated administration of berberine inhibits cytochromes P450 in humans.record2012PMID:218701062 findings
Other names
5 names
Resolves to: berberine
- Also called
- 5,6-dihydro-9,10-dimethoxy-1,3-benzodioxolo[5,6-a]benzo[g]quinolizinium7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-[methylenebis(oxy)]berbinium9,10-dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetradehydroberbiniumUmbellatine
- Systematic name
- 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium